Document:

Exhibit 4.6

                  SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE

                                    AGREEMENT

                          Dated as of September 5, 2007

                                      among

                                 DENTALSERV.COM

                                       and

                       THE PURCHASERS LISTED ON EXHIBIT A

<PAGE>

                                TABLE OF CONTENTS
                                -----------------

                                                                            PAGE
                                                                            ----

ARTICLE I Purchase and Sale of Preferred Stock................................ 1
    Section 1.1   Purchase and Sale of Stock.................................. 1
    Section 1.2   Warrants.................................................... 1
    Section 1.3   Conversion Shares........................................... 2
    Section 1.4   Purchase Price and Closing.................................. 2

ARTICLE II Representations and Warranties..................................... 2
    Section 2.1   Representations and Warranties of the Company............... 2
    Section 2.2   Representations and Warranties of the Purchasers........... 12

ARTICLE III Covenants........................................................ 15
    Section 3.1   Securities Compliance...................................... 15
    Section 3.2   Registration and Listing................................... 15
    Section 3.3   Inspection Rights.......................................... 16
    Section 3.4   Compliance with Laws....................................... 16
    Section 3.5   Keeping of Records and Books of Account.................... 16
    Section 3.6   Reporting Requirements..................................... 16
    Section 3.7   Amendments................................................. 17
    Section 3.8   Other Agreements........................................... 17
    Section 3.9   Distributions.............................................. 17
    Section 3.10  Status of Dividends........................................ 17
    Section 3.11  Use of Proceeds............................................ 18
    Section 3.12  Reservation of Shares...................................... 18
    Section 3.13  Transfer Agent Instructions................................ 18
    Section 3.14  Disposition of Assets...................................... 19
    Section 3.15  Disclosure of Transaction ................................. 19
    Section 3.16  Disclosure of Material Information......................... 19
    Section 3.17  Pledge of Securities....................................... 20
    Section 3.18  Form SB-2 Eligibility...................................... 20
    Section 3.19  Lock-Up Agreement.......................................... 20
    Section 3.20  Investor Relations Firm.................................... 20
    Section 3.21  Reverse Split of Outstanding Shares ....................... 20
    Section 3.22  Authorization of Preferred Shares.......................... 21
    Section 3.23  Increase in Authorized Shares.............................. 21
    Section 3.24  Subsequent Financings ..................................... 21

ARTICLE IV Conditions ....................................................... 22
    Section 4.1   Conditions Precedent to the Obligation of the
                  Company to Sell the Shares................................. 22
    Section 4.2   Conditions Precedent to the Obligation of the
                  Purchasers to Purchase the Shares.......................... 23

<PAGE>

ARTICLE V Stock Certificate Legend........................................... 25
    Section 5.1   Legend..................................................... 25

ARTICLE VI Indemnification................................................... 26
    Section 6.1   General Indemnity.......................................... 26
    Section 6.2   Indemnification Procedure.................................. 26

ARTICLE VII Miscellaneous.................................................... 28
    Section 7.1   Fees and Expenses.......................................... 28
    Section 7.2   Specific Enforcement, Consent to Jurisdiction.............. 28
    Section 7.3   Entire Agreement; Amendment................................ 29
    Section 7.4   Notices.................................................... 29
    Section 7.5   Waivers.................................................... 30
    Section 7.6   Headings................................................... 30
    Section 7.7   Successors and Assigns..................................... 30
    Section 7.8   No Third Party Beneficiaries............................... 30
    Section 7.9   Governing Law.............................................. 30
    Section 7.10  Survival................................................... 30
    Section 7.11  Counterparts............................................... 30
    Section 7.12  Publicity.................................................. 31
    Section 7.13  Severability............................................... 31
    Section 7.14  Further Assurances......................................... 31

                                      ii
<PAGE>

             SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

      This  SERIES  A  CONVERTIBLE   PREFERRED  STOCK  PURCHASE  AGREEMENT  (the
"Agreement")  is dated as of September 5, 2007, by and among  Dentalserv.com,  a
Nevada  corporation  (the  "Company"),  and each of the  Purchasers of shares of
Series A Convertible Preferred Stock of the Company whose names are set forth on
Exhibit  A  hereto   (individually,   a  "Purchaser"   and   collectively,   the
"Purchasers").

      The parties hereto agree as follows:

                                   ARTICLE I
                      Purchase and Sale of Preferred Stock

            Section 1.1 Purchase and Sale of Stock. Upon the following terms and
conditions,  the Company shall issue and sell to the  Purchasers and each of the
Purchasers  shall purchase from the Company,  6,668,230  shares of the Company's
Series A Convertible  Preferred Stock, par value $0.01 per share (the "Preferred
Shares") for an aggregate purchase price of $13,000,000, convertible into shares
of the Company's  common stock,  par value $0.01 per share (the "Common Stock"),
in the amounts set forth opposite such Purchaser's name on Exhibit A hereto. The
designation,  rights, preferences and other terms and provisions of the Series A
Convertible  Preferred  Stock are set forth in the Certificate of Designation of
the Relative Rights and Preferences of the Series A Convertible  Preferred Stock
attached hereto as Exhibit B (the "Certificate of Designation"). The Company and
the Purchasers are executing and  delivering  this Agreement in accordance  with
and in reliance upon the exemption from securities registration afforded by Rule
506 of  Regulation  D  ("Regulation  D") as  promulgated  by the  United  States
Securities and Exchange  Commission (the "Commission")  under the Securities Act
of 1933,  as amended (the  "Securities  Act") or Section 4(2) of the  Securities
Act.

            Section 1.2 Warrants.  Upon the following  terms and  conditions and
for no  additional  consideration,  each of the  Purchasers  shall be issued (i)
Series A Warrants, in substantially the form attached hereto as Exhibit C-1 (the
"Series A Warrants"),  to purchase 6,668,230 shares of Common Stock, (ii) Series
B  Warrants,  in  substantially  the form  attached  hereto as Exhibit  C-2 (the
"Series B Warrants"), to purchase 6,668,230 shares of Common Stock, (iii) Series
J  Warrants,  in  substantially  the form  attached  hereto as Exhibit  C-3 (the
"Series J Warrants"),  to purchase  5,975,116  shares of Common Stock,  provided
that such Purchaser  purchases Preferred Shares for a purchase price equal to or
greater than $5,000,000  pursuant to the terms of this  Agreement,  as set forth
opposite such Purchaser's name on Exhibit A hereto,  and, provided further that,
the  terms  of  exercise  of the  Series J  Warrants  (along  with the  Series C
Warrants)  shall be at an amount  twenty  percent (20%) higher than the terms of
conversion of the Series A and Series B Warrants and (iv) Series C Warrants,  in
substantially  the form attached  hereto as Exhibit C-4, shall be issued to such
Purchaser  to  purchase   5,975,116  shares  of  Common  Stock  (the  "Series  C
Warrants"),  provided  that,  the Series C Warrants shall only be exercisable to
the extent the Series J Warrant has been exercised  (the Series A Warrants,  the
Series B  Warrants,  the  Series J  Warrants  and the  Series C  Warrants  shall
collectively be known herein as, the "Warrants"). The Warrants shall expire five
(5) years  following the Closing Date,  except for the Series J Warrants,  which
shall  expire  fifteen  (15)  months  following  the Closing

<PAGE>

Date.  Each of the Warrants  shall have an exercise price per share equal to the
Warrant Price (as defined in the applicable Warrant).

            Section  1.3  Conversion  Shares/Warrant  Shares.  The  Company  has
authorized  and has  reserved  and  covenants  to continue  to reserve,  free of
preemptive rights and other similar contractual rights of stockholders, a number
of shares of Common Stock equal to the number of shares of Common Stock that are
not  currently  issued or reserved for  issuance;  provided,  however,  upon the
Company  filing the Charter  Amendment (as defined in Section 3.23 hereof),  the
Company shall authorize and reserve and continue to reserve,  free of preemptive
rights and other similar contractual rights of stockholders,  a number of shares
of Common  Stock  equal to one  hundred  fifty  percent  (150%) of the number of
shares of Common  Stock as shall from time to time be  sufficient  to effect the
conversion  of all of the  Preferred  Shares and exercise of the  Warrants  then
outstanding.  Any  shares  of  Common  Stock  issuable  upon  conversion  of the
Preferred  Shares and exercise of the Warrants (and such shares when issued) are
herein  referred  to as  the  "Conversion  Shares"  and  the  "Warrant  Shares",
respectively. The Preferred Shares, the Conversion Shares and the Warrant Shares
are sometimes  collectively  referred to as the  "Shares".

            Section 1.4  Purchase  Price and  Closing.  Subject to the terms and
conditions  hereof,  the Company agrees to issue and sell to the Purchasers and,
in  consideration   of  and  in  express  reliance  upon  the   representations,
warranties,  covenants,  terms and conditions of this Agreement, the Purchasers,
severally  but not  jointly,  agree to  purchase  the  Preferred  Shares and the
Warrants  for an  aggregate  purchase  price of not less than  $13,000,000  (the
"Purchase Price").  The closing of the purchase and sale of the Preferred Shares
and the Warrants to be acquired by the  Purchasers  from the Company  under this
Agreement shall take place at the offices of Lord Bissell & Brook LLP, 885 Third
Avenue,  26th Floor,  New York, NY 10022 (the "Closing") at 10:00 a.m., New York
time on such date as the  Purchasers  and the Company may agree upon;  provided,
that all of the  conditions set forth in Article IV hereof and applicable to the
Closing shall have been fulfilled or waived in accordance herewith (the "Closing
Date").  Subject to the terms and conditions of this  Agreement,  at the Closing
the Company  shall  deliver or cause to be  delivered  to each  Purchaser  (x) a
certificate  for the number of Preferred  Shares set forth  opposite the name of
such Purchaser on Exhibit A hereto,  (y) its Warrants to purchase such number of
shares of Common Stock as is set forth  opposite  the name of such  Purchaser on
Exhibit A attached hereto and (z) any other  documents  required to be delivered
pursuant to Article IV hereof. At the Closing,  each Purchaser shall deliver its
Purchase  Price by wire  transfer to the escrow  account  pursuant to the Escrow
Agreement (as hereafter defined).

                                   ARTICLE II

                         Representations and Warranties

            Section 2.1  Representations  and  Warranties  of the  Company.  The
Company hereby represents and warrants to the Purchasers,  as of the date hereof
and the Closing Date (except as set forth on the Schedule of Exceptions attached
hereto with each numbered Schedule  corresponding to the section number herein),
as  follows:

                                       2
<PAGE>

            (a)  Organization,  Good  Standing  and  Power.  The  Company  is  a
corporation duly  incorporated,  validly existing and in good standing under the
laws of the State of Nevada and has the requisite  corporate power to own, lease
and operate its  properties  and assets and to conduct its business as it is now
being conducted.  The Company does not have any subsidiaries except as set forth
in  Schedule  2.1(a)  hereof.  The  Company  and each  such  subsidiary  is duly
qualified as a foreign  corporation  to do business  and is in good  standing in
every  jurisdiction  in which the nature of the  business  conducted or property
owned by it makes such  qualification  necessary except for any  jurisdiction(s)
(alone or in the  aggregate)  in which the failure to be so  qualified  will not
have a Material  Adverse  Effect (as  defined in Section  2.1(c)  hereof) on the
Company's financial condition.

            (b)  Authorization;  Enforcement.  The  Company  has  the  requisite
corporate  power and  authority  to enter into and perform this  Agreement,  the
Registration  Rights  Agreement  in the form  attached  hereto as Exhibit D (the
"Registration  Rights Agreement"),  the Lock-Up Agreement (as defined in Section
3.20 hereof) in the form attached  hereto as Exhibit E, the Escrow  Agreement by
and among the Company, the Purchasers and the escrow agent, dated as of the date
hereof,  substantially  in the form of Exhibit F attached  hereto  (the  "Escrow
Agreement"),  the Irrevocable Transfer Agent Instructions (as defined in Section
3.13),  the  Certificate of  Designation,  and the Warrants  (collectively,  the
"Transaction  Documents")  and to issue and sell the Shares and the  Warrants in
accordance with the terms hereof. The execution, delivery and performance of the
Transaction  Documents  by  the  Company  and  the  consummation  by it  of  the
transactions  contemplated  hereby  and  thereby  have  been  duly  and  validly
authorized  by all  necessary  corporate  action,  and  no  further  consent  or
authorization  of the  Company  or its Board of  Directors  or  stockholders  is
required.  This  Agreement  has been duly executed and delivered by the Company.
The other  Transaction  Documents  will have been duly executed and delivered by
the Company at the Closing.  Each of the Transaction Documents  constitutes,  or
shall constitute when executed and delivered,  a valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except
as such  enforceability  may be limited by  applicable  bankruptcy,  insolvency,
reorganization,   moratorium,  liquidation,  conservatorship,   receivership  or
similar laws relating to, or affecting  generally the enforcement of, creditor's
rights and remedies or by other equitable principles of general application.

            (c) Capitalization.  The authorized capital stock of the Company and
the shares thereof  currently  issued and  outstanding as of the date hereof are
set forth on Schedule 2.1(c) hereto. All of the outstanding shares of the Common
Stock and the Preferred Shares have been duly and validly authorized.  Except as
set forth on Schedule  2.1(c) hereto,  no shares of Common Stock are entitled to
preemptive rights or registration  rights and there are no outstanding  options,
warrants,  scrip,  rights to subscribe to, call or  commitments of any character
whatsoever  relating to, or securities or rights convertible into, any shares of
capital   stock  of  the   Company.   There  are  no   contracts,   commitments,
understandings,  or  arrangements by which the Company is or may become bound to
issue  additional  shares  of the  capital  stock  of the  Company  or  options,
securities  or rights  convertible  into shares of capital stock of the Company.
Except  as  set  forth  on  Schedule  2.1(c)  hereto,  or  contemplated  by  the
Transaction  Documents,  the  Company is not a party to any  agreement  granting
registration  or  anti-dilution  rights to any person with respect to any of its
equity  or  debt  securities.  The  Company  is not a  party  to,  and it has no
knowledge of, any agreement  restricting the voting or transfer of any shares of
the capital

                                       3
<PAGE>

stock of the Company,  except for the Transaction Documents.  The offer and sale
of all capital stock,  convertible securities,  rights,  warrants, or options of
the Company issued prior to the Closing complied with all applicable Federal and
state securities laws, and no stockholder has a right of rescission or claim for
damages  with respect  thereto  which would have a Material  Adverse  Effect (as
defined  below).  The Company has furnished or made  available to the Purchasers
true and correct copies of the Company's  Articles of Incorporation as in effect
on the date hereof (the  "Articles"),  and the Company's  Bylaws as in effect on
the date hereof (the "Bylaws").  For the purposes of this  Agreement,  "Material
Adverse Effect" means any material  adverse effect on the business,  operations,
properties,   prospects,   or  financial   condition  of  the  Company  and  its
subsidiaries  and/or  any  condition,  circumstance,  or  situation  that  would
prohibit or otherwise  materially  interfere  with the ability of the Company to
perform any of its obligations under this Agreement in any material respect,  or
to conduct its business in the ordinary course.

            (d) Issuance of Shares.  The Preferred Shares and the Warrants to be
issued at the  Closing  have been duly  authorized  by all  necessary  corporate
action and the Preferred Shares,  when paid for or issued in accordance with the
terms  hereof,  shall  be  validly  issued  and  outstanding,   fully  paid  and
nonassessable  and  entitled  to the  rights  and  preferences  set forth in the
Certificate of  Designation.  When the Conversion  Shares and the Warrant Shares
are issued in accordance  with the terms of the  Certificate of Designation  and
the Warrants, respectively, such shares will be duly authorized by all necessary
corporate   action  and  validly   issued  and   outstanding,   fully  paid  and
nonassessable,  and the holders  shall be  entitled to all rights  accorded to a
holder  of  Common  Stock.

            (e) No Conflicts.  The  execution,  delivery and  performance of the
Transaction  Documents by the  Company,  the  performance  by the Company of its
obligations  under the  Certificate of Designation  and the  consummation by the
Company of the transactions  contemplated herein and therein do not and will not
(i) violate any  provision of the  Company's  Articles or Bylaws,  (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or
both would become a default) under, or give to others any rights of termination,
amendment,  acceleration or cancellation  of, any agreement,  mortgage,  deed of
trust, indenture, note, bond, license, lease agreement, instrument or obligation
to which the Company is a party or by which it or its  properties  or assets are
bound, (iii) create or impose a lien,  mortgage,  security  interest,  charge or
encumbrance  of any nature on any property of the Company under any agreement or
any  commitment to which the Company is a party or by which the Company is bound
or by which any of its respective properties or assets are bound, or (iv) result
in  a  violation  of  any  federal,  state,  local  or  foreign  statute,  rule,
regulation,  order,  judgment or decree (including  Federal and state securities
laws and regulations  assuming the representations made by the Purchasers herein
are true and correct) applicable to the Company or any of its subsidiaries or by
which any property or asset of the Company or any of its  subsidiaries are bound
or affected,  except, in all cases other than violations pursuant to clauses (i)
and  (iv)  above,  for  such  conflicts,  defaults,  terminations,   amendments,
accelerations, cancellations and violations as would not, individually or in the
aggregate,  have a Material Adverse Effect.  The business of the Company and its
subsidiaries  is not being  conducted in violation  of any laws,  ordinances  or
regulations of any  governmental  entity,  except for possible  violations which
singularly  or in the  aggregate  do not and will not  have a  Material  Adverse
Effect. The Company is not required

                                       4
<PAGE>

under  Federal,  state or local law,  rule or  regulation to obtain any consent,
authorization or order of, or make any filing or registration with, any court or
governmental  agency in order for it to  execute,  deliver or perform any of its
obligations  under the  Transaction  Documents,  or issue and sell the Preferred
Shares, the Warrants, the Conversion Shares and the Warrant Shares in accordance
with the terms hereof or thereof  (other than any filings  which may be required
to be made by the Company with the Commission or state securities administrators
subsequent  to the  Closing,  any  registration  statement  which  may be  filed
pursuant hereto, the Certificate of Designation and any other filings to be made
with  the  Nevada  Secretary  of State or as  would  not be  expected  to have a
Material Adverse Effect).

            (f) Commission Documents,  Financial Statements.  At the time of the
Closing the Common Stock shall be registered  pursuant to Section 12(b) or 12(g)
of the  Securities  Exchange Act of 1934,  as amended the "Exchange  Act").  The
Company has not provided to the Purchasers any material  non-public  information
or other information which, according to applicable law, rule or regulation, was
required to have been  disclosed  publicly by the Company but which has not been
so disclosed,  other than with respect to the transactions  contemplated by this
Agreement.  The financial  statements of the Company  provided to the Purchasers
(the "Financial Statements") were true and accurate and contain no misstatements
of  material  fact,  except as would not have a Material  Adverse  Effect.  Such
Financial  Statements  have been  prepared  in  accordance  with  United  States
generally accepted accounting  principles ("GAAP") applied on a consistent basis
during the periods  involved  (except (i) as may be otherwise  indicated in such
Financial  Statements  or the  notes  thereto  or (ii) in the case of  unaudited
interim  statements,  to the extent  they may not  include  footnotes  or may be
condensed or summary  statements),  and fairly present in all material  respects
the  financial  position  of the Company  and its  subsidiaries  as of the dates
thereof and the results of operations  and cash flows for the periods then ended
(subject,  in the  case  of  unaudited  statements,  to  normal  year-end  audit
adjustments).

            (g) Subsidiaries.  Schedule 2.1(g) hereto sets forth each subsidiary
of the Company,  showing the  jurisdiction of its  incorporation or organization
and showing the percentage of each person's ownership.  For the purposes of this
Agreement,  "subsidiary"  shall mean any corporation or other entity of which at
least a majority of the securities or other  ownership  interest having ordinary
voting power (absolutely or contingently) for the election of directors or other
persons  performing  similar  functions  are  at  the  time  owned  directly  or
indirectly  by the  Company  and/or  any of its other  subsidiaries.  All of the
outstanding shares of capital stock of each subsidiary have been duly authorized
and  validly  issued,  and  are  fully  paid  and  nonassessable.  There  are no
outstanding  preemptive,  conversion  or  other  rights,  options,  warrants  or
agreements  granted or issued by or binding upon any subsidiary for the purchase
or  acquisition  of any shares of capital  stock of any  subsidiary or any other
securities  convertible  into,  exchangeable  for or  evidencing  the  rights to
subscribe  for any shares of such  capital  stock.  Neither  the Company nor any
subsidiary is subject to any obligation  (contingent or otherwise) to repurchase
or otherwise acquire or retire any shares of the capital stock of any subsidiary
or any convertible securities, rights, warrants or options of the type described
in the preceding  sentence.  Neither the Company nor any subsidiary is party to,
nor has any knowledge of, any  agreement  restricting  the voting or transfer of
any shares of the capital stock of any subsidiary.

            (h) No Material Adverse Change. Since December 31, 2006, the Company

                                       5
<PAGE>

has not experienced or suffered any Material Adverse Effect.

            (i) No Undisclosed  Liabilities.  Neither the Company nor any of its
subsidiaries  has  any  liabilities,  obligations,  claims  or  losses  (whether
liquidated or unliquidated,  secured or unsecured, absolute, accrued, contingent
or otherwise)  other than those incurred in the ordinary course of the Company's
or its  subsidiaries  respective  businesses  since December 31, 2006 and which,
individually  or in the aggregate,  do not or would not have a Material  Adverse
Effect on the Company or its subsidiaries.

            (j) No Undisclosed  Events or Circumstances.  Except as set forth on
Schedule 2.1(j), no event or circumstance has occurred or exists with respect to
the Company or its  subsidiaries  or their  respective  businesses,  properties,
prospects,  operations or financial condition, which, under applicable law, rule
or regulation,  requires  public  disclosure or  announcement by the Company but
which has not been so publicly announced or disclosed to the Purchasers.

            (k) Indebtedness.  Schedule 2.1(k) hereto sets forth as of March 31,
2007, all outstanding  secured and unsecured  Indebtedness of the Company or any
subsidiary, or for which the Company or any subsidiary has commitments.  For the
purposes of this  Agreement,  "Indebtedness"  shall mean (a) any liabilities for
borrowed money or amounts owed in excess of $100,000  (other than trade accounts
payable  incurred  in the  ordinary  course of  business),  (b) all  guaranties,
endorsements  and other  contingent  obligations in respect of  Indebtedness  of
others,  whether  or not the same are or should be  reflected  in the  Company's
balance  sheet (or the notes  thereto),  except  guaranties  by  endorsement  of
negotiable  instruments for deposit or collection or similar transactions in the
ordinary course of business;  and (c) the present value of any lease payments in
excess of $25,000 due under leases required to be capitalized in accordance with
GAAP.  Except as set forth on  Schedule  2.1(k),  neither  the  Company  nor any
subsidiary is in default with respect to any Indebtedness.

            (l) Title to Assets.  Each of the Company and the  subsidiaries  has
good and marketable title to all of its real and personal property  reflected in
Schedule  2.1(l),  free and clear of any  mortgages,  pledges,  charges,  liens,
security interests or other encumbrances, except for those disclosed in Schedule
2.1(l) or such that,  individually or in the aggregate,  do not cause a Material
Adverse Effect. All leases of the Company and each of its subsidiaries are valid
and subsisting and in full force and effect.

            (m) Actions Pending.  Except as disclosed on Schedule 2.1(m),  there
is  no  action,  suit,  claim,  investigation,  arbitration,  alternate  dispute
resolution  proceeding or any other  proceeding  pending or, to the knowledge of
the Company,  threatened  against the Company or any subsidiary  which questions
the validity of this Agreement or any of the other Transaction  Documents or the
transactions  contemplated  hereby or thereby or any action taken or to be taken
pursuant  hereto or thereto.  There is no action,  suit,  claim,  investigation,
arbitration,  alternate  dispute  resolution  proceeding or any other proceeding
pending or, to the  knowledge of the Company,  threatened,  against or involving
the Company,  any  subsidiary or any of their  respective  properties or assets.
There are no outstanding orders,  judgments,  injunctions,  awards or decrees of
any court,  arbitrator or governmental or regulatory body against the Company or

                                       6
<PAGE>

any  subsidiary  or any officers or directors  of the Company or  subsidiary  in
their capacities as such.

            (n)  Compliance  with  Law.  The  business  of the  Company  and the
subsidiaries  has been and is presently  being  conducted in accordance with all
applicable  federal,  state and local governmental laws, rules,  regulations and
ordinances,   except  for  such  noncompliance  that,  individually  or  in  the
aggregate,  would not cause a Material  Adverse Effect.  The Company and each of
its  subsidiaries  have all franchises,  permits,  licenses,  consents and other
governmental  or  regulatory  authorizations  and  approvals  necessary  for the
conduct of its  business  as now being  conducted  by it unless  the  failure to
possess such franchises,  permits, licenses,  consents and other governmental or
regulatory authorizations and approvals, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect.

            (o) Taxes.  Except as disclosed on Schedule 2.1(o),  the Company and
each of the  subsidiaries has accurately  prepared and filed all federal,  state
and  other  tax  returns  required  by law to be filed  by it,  has paid or made
provisions  for the  payment  of all  taxes  shown to be due and all  additional
assessments,  and  adequate  provisions  have  been  and  are  reflected  in the
financial  statements of the Company and the  subsidiaries for all current taxes
and other  charges to which the Company or any  subsidiary  is subject and which
are not currently due and payable. None of the federal income tax returns of the
Company or any subsidiary have been audited by the Internal Revenue Service. The
Company  has  no  knowledge  of  any  additional  assessments,   adjustments  or
contingent tax liability  (whether  federal or state) of any nature  whatsoever,
whether  pending or  threatened  against the Company or any  subsidiary  for any
period, nor of any basis for any such assessment, adjustment or contingency.

            (p)  Certain  Fees.  Except  for the fees  being  paid to SC Capital
Partners,  LLC in  connection  with the  transactions  contemplated  hereby,  no
brokers,  finders or financial  advisory fees or commissions  will be payable by
the Company or any subsidiary or any Purchaser with respect to the  transactions
contemplated by this Agreement.

            (q) Disclosure.  Neither this Agreement or the Schedules  hereto nor
any other documents,  certificates or instruments furnished to the Purchasers by
or  on  behalf  of  the  Company  or  any  subsidiary  in  connection  with  the
transactions  contemplated by this Agreement  contain any untrue  statement of a
material  fact or omit to state a material  fact  necessary in order to make the
statements made herein or therein, in the light of the circumstances under which
they were made herein or therein, not misleading.

            (r) Operation of Business.  The Company and each of the subsidiaries
owns  or  possesses  all  patents,  trademarks,  domain  names  (whether  or not
registered) and any patentable  improvements or  copyrightable  derivative works
thereof,  websites and intellectual  property rights relating  thereto,  service
marks,  trade names,  copyrights,  licenses and  authorizations  as set forth in
Schedule  2.1(r),  and all  rights  with  respect  to the  foregoing,  which are
necessary for the conduct of its business as now conducted  without any conflict
with the rights of others.

            (s)   Environmental   Compliance.   The  Company  and  each  of  its
subsidiaries

                                       7
<PAGE>

have obtained all material  approvals,  authorization,  certificates,  consents,
licenses, orders and permits or other similar authorizations of all governmental
authorities, or from any other person, that are required under any Environmental
Laws.  Schedule  2.1(s)  describes  all  material  permits,  licenses  and other
authorizations  issued  under  any  Environmental  Laws  to the  Company  or its
subsidiaries.  "Environmental  Laws" shall mean all applicable  laws relating to
the  protection  of  the  environment   including,   without   limitation,   all
requirements  pertaining  to  reporting,  licensing,  permitting,   controlling,
investigating  or  remediating  emissions,  discharges,  releases or  threatened
releases of hazardous substances, chemical substances, pollutants,  contaminants
or toxic substances,  materials or wastes,  whether solid,  liquid or gaseous in
nature,  into the air,  surface  water,  groundwater or land, or relating to the
manufacture,   processing,  distribution,  use,  treatment,  storage,  disposal,
transport or handling of hazardous substances, chemical substances,  pollutants,
contaminants or toxic substances,  material or wastes,  whether solid, liquid or
gaseous in nature. The Company has all necessary governmental approvals required
under all Environmental  Laws and used in its business or in the business of any
of its  subsidiaries.  The  Company  and  each of its  subsidiaries  are also in
compliance  with all other  limitations,  restrictions,  conditions,  standards,
requirements,   schedules   and   timetables   required  or  imposed  under  all
Environmental  Laws.  Except for such instances as would not  individually or in
the  aggregate  have a  Material  Adverse  Effect,  there are no past or present
events, conditions,  circumstances,  incidents, actions or omissions relating to
or in any way  affecting  the Company or its  subsidiaries  that  violate or may
violate any  Environmental  Law after the Closing  Date or that may give rise to
any environmental  liability,  or otherwise form the basis of any claim, action,
demand,  suit,  proceeding,  hearing,  study  or  investigation  (i)  under  any
Environmental  Law, or (ii) based on or related to the manufacture,  processing,
distribution,  use, treatment, storage (including without limitation underground
storage tanks),  disposal,  transport or handling,  or the emission,  discharge,
release or threatened release of any hazardous substance.

            (t) Books and Record  Internal  Accounting  Controls.  The books and
records of the Company and its subsidiaries  accurately  reflect in all material
respects  the  information  relating  to the  business  of the  Company  and the
subsidiaries, the location and collection of their assets, and the nature of all
transactions  giving  rise to the  obligations  or  accounts  receivable  of the
Company or any subsidiary.  The Company and each of its subsidiaries  maintain a
system of  internal  accounting  controls  sufficient,  in the  judgment  of the
Company,  to provide reasonable  assurance that (i) transactions are executed in
accordance  with   management's   general  or  specific   authorizations,   (ii)
transactions  are  recorded as  necessary  to permit  preparation  of  financial
statements in conformity with GAAP and to maintain asset  accountability,  (iii)
access to assets is permitted only in accordance  with  management's  general or
specific  authorization  and (iv) the  recorded  accountability  for  assets  is
compared  with the  existing  assets at  reasonable  intervals  and  appropriate
actions is taken with respect to any differences.

            (u) Material Agreements.  Except as set forth on Schedule 2.1(u) and
the Transaction Documents themselves,  neither the Company nor any subsidiary is
a party to any  written or oral  contract,  instrument,  agreement,  commitment,
obligation,  plan or arrangement,  a copy of which would be required to be filed
with the  Commission  as an exhibit to a  registration  statement on Form S-3 or
applicable  form  (collectively,  "Material  Agreements")  if the Company or any
subsidiary were registering securities under the Securities Act. The Company and
each  of its  subsidiaries  has in  all  material  respects  performed  all  the
obligations  required  to be  performed

                                       8
<PAGE>

by them to date  under the  foregoing  agreements,  have  received  no notice of
default and are not in default under any Material  Agreement now in effect,  the
result of which  could  cause a  Material  Adverse  Effect.  No  written or oral
contract, instrument, agreement, commitment,  obligation, plan or arrangement of
the Company or of any subsidiary  limits or shall limit the payment of dividends
on the Company's Preferred Shares,  other preferred stock, if any, or its Common
Stock, except for the Transaction Documents.

            (v) Transactions  with  Affiliates.  Except as set forth on Schedule
2.1(v)  hereof,  there  are no loans,  leases,  agreements,  contracts,  royalty
agreements,   management   contracts  or   arrangements   or  other   continuing
transactions  between (a) the Company or any subsidiary on the one hand, and (b)
on the other hand, any officer, employee, consultant or director of the Company,
or any of its  subsidiaries,  or any  person  owning  any  capital  stock of the
Company or any subsidiary or any member of the immediate family of such officer,
employee, consultant, director or stockholder or any corporation or other entity
controlled by such officer, employee, consultant,  director or stockholder, or a
member of the immediate family of such officer, employee,  consultant,  director
or stockholder.

            (w)  Securities  Act of  1933.  Based  in  material  part  upon  the
representations  herein of the  Purchasers,  the Company has  complied  and will
comply with all applicable  federal and state securities laws in connection with
the offer,  issuance and sale of the Shares and the Warrants hereunder.  Neither
the Company nor anyone acting on its behalf, directly or indirectly, has or will
sell, offer to sell or solicit offers to buy any of the Shares,  the Warrants or
similar  securities  to, or solicit  offers with respect  thereto from, or enter
into any preliminary  conversations  or negotiations  relating thereto with, any
person,  or has taken or will take any  action so as to bring the  issuance  and
sale of any of the Shares and the Warrants under the registration  provisions of
the Securities Act and applicable state securities laws, and neither the Company
nor any of its  affiliates,  nor any person acting on its or their  behalf,  has
engaged in any form of general  solicitation or general  advertising (within the
meaning of Regulation D under the Securities  Act) in connection  with the offer
or sale of any of the Shares and the Warrants.

            (x)  Governmental  Approvals.  Except  for the  filing of any notice
prior or  subsequent to the Closing Date that may be required  under  applicable
state and/or  Federal  securities  laws (which if required,  shall be filed on a
timely basis),  including the filing of a Form D and a registration statement or
statements pursuant to the Registration Rights Agreement,  and the filing of the
Certificate of Designation and other filings with the Secretary of State for the
State of Nevada, no authorization,  consent,  approval,  license,  exemption of,
filing or registration  with any court or governmental  department,  commission,
board,  bureau,  agency or  instrumentality,  domestic or foreign, is or will be
necessary for, or in connection with, the execution or delivery of the Preferred
Shares  and  the  Warrants,  or  for  the  performance  by  the  Company  of its
obligations under the Transaction Documents.

            (y) Employees.  Except as set forth on Schedule 2.1(y),  neither the
Company  nor  any  subsidiary  has any  collective  bargaining  arrangements  or
agreements  covering  any of its  employees.  Except  as set  forth on  Schedule
2.1(y),  neither the Company nor any  subsidiary  has any  employment  contract,
agreement  regarding   proprietary   information,   non-competition   agreement,
non-solicitation  agreement,  confidentiality  agreement,  or any other  similar
contract

                                       9
<PAGE>

or  restrictive  covenant,  relating  to the right of any  officer,  employee or
consultant  to be  employed  or engaged by the  Company or such  subsidiary.  No
officer,  consultant  or key  employee  of the Company or any  subsidiary  whose
termination,  either  individually  or in the  aggregate,  could have a Material
Adverse  Effect,  has  terminated  or, to the knowledge of the Company,  has any
present  intention of terminating  his or her employment or engagement  with the
Company or any subsidiary.

            (z) Absence of Certain Developments. Except as disclosed on Schedule
2.1(z), since December 31, 2006, neither the Company nor any subsidiary has:

                  (i) issued any stock,  bonds or other corporate  securities or
any rights, options or warrants with respect thereto;

                  (ii) borrowed any amount or incurred or become  subject to any
liabilities  (absolute or contingent) except current liabilities incurred in the
ordinary  course of business  which are  comparable  in nature and amount to the
current  liabilities  incurred in the  ordinary  course of  business  during the
comparable  portion of its prior fiscal year, as adjusted to reflect the current
nature and volume of the Company's or such subsidiary's business;

                  (iii)  discharged or satisfied any lien or encumbrance or paid
any  obligation  or  liability  (absolute  or  contingent),  other than  current
liabilities paid in the ordinary course of business;

                  (iv) declared or made any payment or  distribution  of cash or
other  property to  stockholders  with  respect to its stock,  or  purchased  or
redeemed,  or made any  agreements  so to purchase or redeem,  any shares of its
capital stock;

                  (v) sold,  assigned or transferred any other tangible  assets,
or canceled any debts or claims, except in the ordinary course of business;

                  (vi)  sold,   assigned  or  transferred   any  patent  rights,
trademarks, trade names, copyrights, trade secrets or other intangible assets or
intellectual   property  rights,  or  disclosed  any  proprietary   confidential
information to any person except to customers in the ordinary course of business
or to the Purchasers or their representatives;

                  (vii) suffered any substantial  losses or waived any rights of
material value,  whether or not in the ordinary course of business,  or suffered
the loss of any material amount of prospective business;

                  (viii) made any changes in employee compensation except in the
ordinary course of business and consistent with past practices;

                  (ix) made capital  expenditures  or commitments  therefor that
aggregate in excess of $100,000;

                                       10
<PAGE>

                  (x)  entered  into any  other  transaction  other  than in the
ordinary  course of business,  or entered into any other  material  transaction,
whether or not in the ordinary course of business;

                  (xi) made  charitable  contributions  or  pledges in excess of
$25,000;

                  (xii)  suffered any material  damage,  destruction or casualty
loss, whether or not covered by insurance;

                  (xiii)   experienced  any  material  problems  with  labor  or
management in connection with the terms and conditions of their employment;

                  (xiv)  effected any two or more events of the  foregoing  kind
which in the aggregate would be material to the Company or its subsidiaries; or

                  (xv) entered into an agreement,  written or otherwise, to take
any of the foregoing actions.

            (aa)  Investment  Company Act Status.  The Company is not,  and as a
result of and immediately upon the Closing will not be, an "investment  company"
or a company "controlled" by an "investment  company," within the meaning of the
Investment Company Act of 1940, as amended.

            (bb) ERISA. No liability to the Pension Benefit Guaranty Corporation
has been incurred with respect to any Plan (as defined  below) by the Company or
any of its subsidiaries  which is or would be materially  adverse to the Company
and its  subsidiaries.  The  execution  and delivery of this  Agreement  and the
issuance and sale of the Preferred Shares will not involve any transaction which
is subject to the  prohibitions  of Section 406 of ERISA or in  connection  with
which a tax could be imposed  pursuant to Section 4975 of the  Internal  Revenue
Code of 1986, as amended, provided that, if any of the Purchasers, or any person
or entity  that  owns a  beneficial  interest  in any of the  Purchasers,  is an
"employee  pension  benefit  plan" (within the meaning of Section 3(2) of ERISA)
with respect to which the Company is a "party in  interest"  (within the meaning
of Section 3(14) of ERISA), the requirements of Sections 407(d)(5) and 408(e) of
ERISA, if applicable,  are met. As used in this Section 2.1(ac), the term "Plan"
shall mean an "employee pension benefit plan" (as defined in Section 3 of ERISA)
which is or has been established or maintained, or to which contributions are or
have been made,  by the Company or any  subsidiary  or by any trade or business,
whether or not incorporated, which, together with the Company or any subsidiary,
is under common control, as described in Section 414(b) or (c) of the Code.

            (cc) Dilutive Effect. The Company  understands and acknowledges that
its  obligation  to issue  Conversion  Shares upon  conversion  of the Preferred
Shares in accordance  with this Agreement and the Certificate of Designation and
its obligations to issue the Warrant Shares upon the exercise of the Warrants in
accordance with this Agreement and the Warrants,  is, in each case, absolute and
unconditional  regardless of the dilutive  effect that such issuance may have on
the ownership interest of other stockholders of the Company.

                                       11
<PAGE>

            (dd) No  Integrated  Offering.  Neither the Company,  nor any of its
affiliates,  nor any  person  acting on its or their  behalf,  has  directly  or
indirectly  made any offers or sales of any security or solicited  any offers to
buy any security under circumstances that would cause the offering of the Shares
pursuant to this Agreement to be integrated  with prior offerings by the Company
for purposes of the  Securities Act which would prevent the Company from selling
the Shares  pursuant to Rule 506 under the  Securities  Act,  or any  applicable
exchange-related stockholder approval provisions, nor will the Company or any of
its  affiliates  or  subsidiaries  take any action or steps that would cause the
offering of the Shares to be integrated with other  offerings.  The Company does
not have any registration  statement  pending before the Commission or currently
under the  Commission's  review and since  January 1, 2007,  the Company has not
offered or sold any of its equity securities or debt securities convertible into
shares of Common Stock.

            (ee) Independent Nature of Purchasers. The Company acknowledges that
the obligations of each Purchaser  under the  Transaction  Documents are several
and not joint with the  obligations  of any other  Purchaser,  and no  Purchaser
shall be  responsible in any way for the  performance of the  obligations of any
other Purchaser under the Transaction  Documents.  The Company acknowledges that
the decision of each Purchaser to purchase securities pursuant to this Agreement
has  been  made  by such  Purchaser  independently  of any  other  purchase  and
independently  of any information,  materials,  statements or opinions as to the
business,  affairs,  operations,  assets,  properties,  liabilities,  results of
operations, condition (financial or otherwise) or prospects of the Company or of
its Subsidiaries  which may have been made or given by any other Purchaser or by
any agent or employee of any other  Purchaser,  and no  Purchaser  or any of its
agents or  employees  shall have any  liability to any  Purchaser  (or any other
person) relating to or arising from any such information,  materials, statements
or opinions.  The Company  acknowledges that nothing contained herein, or in any
Transaction  Document,  and no action taken by any Purchaser  pursuant hereto or
thereto,  shall be deemed to  constitute  the  Purchasers as a  partnership,  an
association,  a  joint  venture  or any  other  kind  of  entity,  or  create  a
presumption  that the  Purchasers are in any way acting in concert or as a group
with  respect  to  such  obligations  or the  transactions  contemplated  by the
Transaction  Documents.  The Company  acknowledges  that each Purchaser shall be
entitled to  independently  protect and  enforce its rights,  including  without
limitation,  the  rights  arising  out of  this  Agreement  or out of the  other
Transaction Documents,  and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such purpose. The Company
acknowledges   that  for  reasons  of   administrative   convenience  only,  the
Transaction  Documents  have been prepared by counsel for one of the  Purchasers
and such  counsel  does  not  represent  all of the  Purchasers  but  only  such
Purchaser and the other  Purchasers  have retained their own individual  counsel
with respect to the transactions  contemplated  hereby. The Company acknowledges
that  it has  elected  to  provide  all  Purchasers  with  the  same  terms  and
Transaction  Documents for the convenience of the Company and not because it was
required or requested to do so by the Purchasers.

            (ff) DTC Status.  The Company's  transfer  agent is a participant in
and, as of the time of the  Closing,  the Common  Stock  shall be  eligible  for
transfer pursuant to the Depository Trust Company Automated  Securities Transfer
Program.  The name,  address,  telephone number, fax number,  contact person and
email address of the Company's  transfer agent is set forth on Schedule  2.1(ff)
hereto.

                                       12
<PAGE>

            Section 2.2 Representations  and Warranties of the Purchasers.  Each
Purchaser  hereby makes the  following  representations  and  warranties  to the
Company  with  respect  solely  to  itself  and not with  respect  to any  other
Purchaser:

            (a) Organization and Standing of the Purchasers. If the Purchaser is
an entity,  such Purchaser is a corporation or partnership duly  incorporated or
organized,  validly  existing  and  in  good  standing  under  the  laws  of the
jurisdiction of its incorporation or organization.

            (b)  Authorization and Power. Each Purchaser has the requisite power
and authority to enter into and perform this Agreement and the other Transaction
Documents,  as  applicable,  and to purchase the  Preferred  Shares and Warrants
being sold to it hereunder.  The  execution,  delivery and  performance  of this
Agreement  and the  Registration  Rights  Agreement  by such  Purchaser  and the
consummation by it of the transactions contemplated hereby and thereby have been
duly authorized by all necessary corporate or partnership action, and no further
consent  or   authorization  of  such  Purchaser  or  its  Board  of  Directors,
stockholders,  or  partners,  as the  case  may be,  is  required.  Each of this
Agreement  and the  Registration  Rights  Agreement  has been  duly  authorized,
executed and delivered by such Purchaser and  constitutes,  or shall  constitute
when  executed and  delivered,  a valid and binding  obligation of the Purchaser
enforceable against the Purchaser in accordance with the terms thereof.

            (c) No Conflicts.  The execution,  delivery and  performance of this
Agreement and the  Registration  Rights  Agreement and the  consummation by such
Purchaser of the transactions contemplated hereby and thereby or relating hereto
do not and  will not (i)  result  in a  violation  of such  Purchaser's  charter
documents or bylaws or other organizational  documents or (ii) conflict with, or
constitute  a default  (or an event  which with  notice or lapse of time or both
would  become a default)  under,  or give to others  any rights of  termination,
amendment,   acceleration  or  cancellation  of  any  agreement,   indenture  or
instrument  or  obligation  to which such  Purchaser  is a party or by which its
properties  or assets are bound,  or result in a violation of any law,  rule, or
regulation, or any order, judgment or decree of any court or governmental agency
applicable  to such  Purchaser  or its  properties  (except for such  conflicts,
defaults and violations as would not,  individually or in the aggregate,  have a
material  adverse effect on such  Purchaser).  Such Purchaser is not required to
obtain  any  consent,   authorization  or  order  of,  or  make  any  filing  or
registration with, any court or governmental  agency in order for it to execute,
deliver  or  perform  any  of  its  obligations  under  this  Agreement  or  the
Registration Rights Agreement or to purchase the Preferred Shares or acquire the
Warrants in accordance with the terms hereof,  provided that for purposes of the
representation  made in this  sentence,  such  Purchaser is assuming and relying
upon the accuracy of the relevant  representations and agreements of the Company
herein.

            (d)  Acquisition  for  Investment.  Each  Purchaser is acquiring the
Preferred  Shares and the Warrants solely for its own account for the purpose of
investment and not with a view to or for sale in connection  with  distribution.
Each Purchaser does not have a present intention to sell the Preferred Shares or
the  Warrants,  nor a present  arrangement  (whether or not legally  binding) or
intention to effect any  distribution of the Preferred Shares or the Warrants to
or  through  any  person  or  entity;  provided,  however,  that by  making  the
representations  herein and subject to Section 2.2(h) below, such Purchaser does
not agree to hold the Shares or the

                                       13
<PAGE>

Warrants  for any  minimum  or other  specific  term and  reserves  the right to
dispose of the Shares or the Warrants at any time in accordance with Federal and
state   securities   laws  applicable  to  such   disposition.   Each  Purchaser
acknowledges  that it is able to bear the  financial  risks  associated  with an
investment in the  Preferred  Shares and the Warrants and that it has been given
full  access to such  records of the  Company  and the  subsidiaries  and to the
officers of the Company and the subsidiaries and received such information as it
has deemed  necessary or appropriate to conduct its due diligence  investigation
and has sufficient knowledge and experience in investing in companies similar to
the Company in terms of the Company's  stage of  development so as to be able to
evaluate the risks and merits of its investment in the Company.

            (e) Status of Purchasers. Each Purchaser is an "accredited investor"
as defined in Regulation D promulgated  under the Securities Act. Such Purchaser
is not required to be  registered  as a  broker-dealer  under  Section 15 of the
Exchange Act and such Purchaser is not a broker-dealer.

            (f)  Opportunities  for  Additional   Information.   Each  Purchaser
acknowledges that such Purchaser has had the opportunity to ask questions of and
receive  answers  from, or obtain  additional  information  from,  the executive
officers  of the  Company  concerning  the  financial  and other  affairs of the
Company,  and to the  extent  deemed  necessary  in  light  of such  Purchaser's
personal  knowledge of the  Company's  affairs,  such  Purchaser  has asked such
questions and received answers to the full  satisfaction of such Purchaser,  and
such Purchaser desires to invest in the Company.

            (g) No General  Solicitation.  Each Purchaser  acknowledges that the
Preferred Shares and the Warrants were not offered to such Purchaser by means of
any form of general or public solicitation or general  advertising,  or publicly
disseminated   advertisements   or   sales   literature,   including   (i)   any
advertisement,   article,   notice  or  other  communication  published  in  any
newspaper, magazine, or similar media, or broadcast over television or radio, or
(ii) any  seminar or meeting to which such  Purchaser  was invited by any of the
foregoing means of communications.

            (h) Rule 144.  Such  Purchaser  understands  that the Shares must be
held indefinitely  unless such Shares are registered under the Securities Act or
an exemption from  registration is available.  Such Purchaser  acknowledges that
such  Purchaser is familiar  with Rule 144 of the rules and  regulations  of the
Commission, as amended, promulgated pursuant to the Securities Act ("Rule 144"),
and that such person has been advised  that Rule 144 permits  resales only under
certain  circumstances.  Such Purchaser understands that to the extent that Rule
144 is not  available,  such Purchaser will be unable to sell any Shares without
either  registration  under  the  Securities  Act or the  existence  of  another
exemption from such registration requirement.

            (i) General.  Such Purchaser  understands  that the Shares are being
offered and sold in reliance on a transactional  exemption from the registration
requirement of Federal and state securities laws and the Company is relying upon
the  truth  and  accuracy  of  the  representations,   warranties,   agreements,
acknowledgments  and  understandings of such Purchaser set forth herein in order
to determine the  applicability  of such  exemptions and the suitability of such
Purchaser to acquire the Shares.

                                       14
<PAGE>

            (j)  Independent  Investment.  Except  as  may be  disclosed  in any
filings with the Commission by the Purchasers under Section 13 and/or Section 16
of the Exchange Act, no Purchaser has agreed to act with any other Purchaser for
the purpose of acquiring,  holding,  voting or disposing of the Shares purchased
hereunder  for  purposes  of Section  13(d)  under the  Exchange  Act,  and each
Purchaser is acting independently with respect to its investment in the Shares.

            (k) Trading  Activities.  Each Purchaser's  trading  activities with
respect to the Shares shall be in  compliance  with all  applicable  federal and
state  securities laws. No Purchaser nor any of its affiliates has an open short
position in the Common Stock,  each Purchaser agrees that it shall not, and that
it will cause its  affiliates  not to, engage in any short sales with respect to
the Common Stock. In making its investment decision,  no Purchaser has relied on
any forward looking statements provided to such Purchaser by the Company.

                                   ARTICLE III

                                    Covenants

      The  Company  covenants  with each of the  Purchasers  as  follows,  which
covenants are for the benefit of the  Purchasers and their  permitted  assignees
(as defined herein).

            Section 3.1  Securities  Compliance.  The Company  shall  notify the
Commission in accordance with their rules and  regulations,  of the transactions
contemplated by any of the Transaction Documents, including filing a Form D with
respect to the Preferred Shares, Warrants,  Conversion Shares and Warrant Shares
as required under  Regulation D and  applicable  "blue sky" laws, and shall take
all other  necessary  action and proceedings as may be required and permitted by
applicable  law, rule and  regulation,  for the legal and valid  issuance of the
Preferred Shares, the Warrants,  the Conversion Shares and the Warrant Shares to
the Purchasers or subsequent holders.

            Section 3.2 Registration and Listing. As of the time of the Closing,
the Company shall cause its Common Stock to be registered  under  Sections 12(b)
or 12(g) of the Exchange  Act, to comply in all respects  with its reporting and
filing  obligations  under the  Exchange  Act, to comply  with all  requirements
related to any registration  statement filed pursuant to this Agreement,  and to
not take any  action  or file any  document  (whether  or not  permitted  by the
Securities Act or the rules promulgated thereunder) to terminate or suspend such
registration  or to terminate or suspend its  reporting  and filing  obligations
under the Exchange Act or Securities Act, except as permitted  herein. As of the
time of the Closing,  the Company will take all action necessary for the listing
or trading of its Common  Stock on the OTC Bulletin  Board or other  exchange or
market on which the Common  Stock is trading  and shall  ensure  that its Common
Stock shall continue to be traded on the OTC Bulletin Board or other exchange of
market on which its  Common  Stock may be traded in the  future.  Subject to the
terms of the Transaction  Documents,  the Company further covenants that it will
take such further action as the Purchasers  may reasonably  request,  all to the
extent  required  from time to time to enable the  Purchasers to sell the Shares
without  registration  under the  Securities  Act within the  limitation  of the
exemptions  provided by Rule 144 promulgated  under the Securities

                                       15
<PAGE>

Act.  Upon the  request of the  Purchasers,  the  Company  shall  deliver to the
Purchasers a written certification of a duly authorized officer as to whether it
has complied with such requirements.

            Section 3.3  Inspection  Rights.  The Company shall  permit,  during
normal business hours and upon reasonable  request and reasonable  notice,  each
Purchaser or any employees,  agents or representatives  thereof, so long as such
Purchaser shall be obligated hereunder to purchase the Preferred Shares or shall
beneficially own any Preferred  Shares, or shall own Conversion Shares which, in
the aggregate,  represent more than 1% of the total combined voting power of all
voting  securities then  outstanding,  for purposes  reasonably  related to such
Purchaser's  interests as a stockholder to examine and make reasonable copies of
and extracts from the records and books of account of, and visit and inspect the
properties,  assets,  operations and business of the Company and any subsidiary,
and to discuss  the  affairs,  finances  and  accounts  of the  Company  and any
subsidiary with any of its officers, consultants,  directors, and key employees,
provided,  however,  that the Company  shall not provide to or discuss with such
Purchaser  any  material  non-public  information,  unless  prior  thereto  such
Purchaser shall have executed a written agreement  regarding the confidentiality
and use of such information.

            Section 3.4  Compliance  with Laws.  The Company shall  comply,  and
cause each subsidiary to comply,  with all applicable laws,  rules,  regulations
and orders, noncompliance with which could have a Material Adverse Effect.

            Section 3.5  Keeping of Records  and Books of  Account.  The Company
shall keep and cause  each  subsidiary  to keep  adequate  records  and books of
account,  in  which  complete  entries  will  be made in  accordance  with  GAAP
consistently applied,  reflecting all financial  transactions of the Company and
its  subsidiaries,  and in which,  for each fiscal year, all proper reserves for
depreciation, depletion, obsolescence,  amortization, taxes, bad debts and other
purposes in connection with its business shall be made.

            Section 3.6 Reporting Requirements.  If the Commission ceases making
periodic  reports filed under the Exchange Act available via the Internet,  then
at a  Purchaser's  request  the Company  shall  furnish  the  following  to such
Purchaser so long as such Purchaser shall be obligated hereunder to purchase the
Preferred Shares or shall beneficially own any Shares:

            (a) Quarterly  Reports  filed with the  Commission on Form 10-QSB as
soon as practical  after the document is filed with the  Commission,  and in any
event within five (5) days after the document is filed with the Commission;

            (b) Annual  Reports filed with the Commission on Form 10-KSB as soon
as practical after the document is filed with the  Commission,  and in any event
within five (5) days after the  document is filed with the  Commission;  and

            (c)  Copies  of  all  notices  and  information,  including  without
limitation  notices and proxy  statements in connection with any meetings,  that
are provided to holders of shares of Common  Stock,  contemporaneously  with the
delivery of such notices or information to such holders of Common Stock.

                                       16
<PAGE>

            Section 3.7  Amendments.  The  Company  shall not amend or waive any
provision  of the  Articles  or  Bylaws  of the  Company  in any way that  would
adversely  affect the  liquidation  preferences,  dividends  rights,  conversion
rights, voting rights or redemption rights of the Preferred Shares.

            Section 3.8 Other  Agreements.  The Company shall not enter into any
agreement  in which the terms of such  agreement  would  restrict  or impair the
right  or  ability  to  perform  of the  Company  or any  subsidiary  under  any
Transaction Document.

            Section 3.9 Distributions.  Excluding any items set forth in Section
3.11 hereto, so long as any Preferred Shares or Warrants remain outstanding, the
Company  agrees that it shall not (i) declare or pay any  dividends  or make any
distributions  to any  holder(s) of Common  Stock or (ii)  purchase or otherwise
acquire for value,  directly or  indirectly,  any Common  Stock or other  equity
security of the Company.

            Section 3.10 Status of Dividends.  The Company  covenants and agrees
that (i) no Federal  income tax return or claim for refund of Federal income tax
or other  submission  to the  Internal  Revenue  Service  (the  "Service")  will
adversely affect the Preferred Shares,  any other series of its Preferred Stock,
or  the  Common  Stock,  and  no  deduction  shall  operate  to  jeopardize  the
availability  to  Purchasers  of the dividends  received  deduction  provided by
Section 243(a)(1) of the Code or any successor  provision,  (ii) in no report to
shareholders or to any governmental body having jurisdiction over the Company or
otherwise will it treat the Preferred Shares other than as equity capital or the
dividends  paid thereon other than as dividends  paid on equity  capital  unless
required to do so by a governmental  body having  jurisdiction over the accounts
of the  Company  or by a change  in  generally  accepted  accounting  principles
required as a result of action by an authoritative  accounting standards setting
body,  and (iii) it will take no action which would result in the dividends paid
by the  Company  on  the  Preferred  Shares  out of  the  Company's  current  or
accumulated  earnings and profits being  ineligible  for the dividends  received
deduction  provided by Section  243(a)(1) of the Code.  The  preceding  sentence
shall not be deemed to prevent the Company from  designating the Preferred Stock
as  "Convertible   Preferred  Stock"  in  its  annual  and  quarterly  financial
statements  in accordance  with its prior  practice  concerning  other series of
preferred stock of the Company. In the event that the Purchasers have reasonable
cause to believe that dividends paid by the Company on the Preferred  Shares out
of the Company's current or accumulated earnings and profits will not be treated
as eligible for the dividends  received  deduction provided by Section 243(a)(1)
of the Code, or any  successor  provision,  the Company will, at the  reasonable
request of the Purchasers of 51% of the outstanding  Preferred Shares, join with
the  Purchasers in the  submission to the Service of a request for a ruling that
dividends  paid on the  Shares  will  be so  eligible  for  Federal  income  tax
purposes. In addition, the Company will reasonably cooperate with the Purchasers
in any  litigation,  appeal or other  proceeding  challenging  or contesting any
ruling, technical advice, finding or determination that earnings and profits are
not eligible for the dividends  received deduction provided by Section 243(a)(1)
of the Code,  or any  successor  provision to the extent that the position to be
taken in any such litigation, appeal, or other proceeding is not contrary to any
provision of the Code.  Notwithstanding the foregoing,  nothing herein contained
shall be deemed to preclude the Company from  claiming a deduction  with respect
to such dividends if (i) the Code shall hereafter be amended,  or final Treasury
regulations  thereunder are issued or

                                       17
<PAGE>

modified, to provide that dividends on the Preferred Shares or Conversion Shares
should not be treated as  dividends  for Federal  income tax  purposes or that a
deduction  with  respect to all or a portion of the  dividends  on the Shares is
allowable  for Federal  income tax  purposes,  or (ii) in the absence of such an
amendment,  issuance or  modification  and after a  submission  of a request for
ruling or technical advice, the Service shall issue a published ruling or advise
that  dividends  on the Shares  should not be treated as  dividends  for Federal
income tax purposes.  If the Service specifically  determines that the Preferred
Shares or Conversion  Shares  constitute  debt, the Company may file  protective
claims for refund.

            Section 3.11 Use of Proceeds.  The net proceeds from the sale of the
Shares hereunder shall be used by the Company as set forth on Schedule 3.11.

            Section 3.12 Reservation of Shares.  So long as any of the Preferred
Shares or  Warrants  remain  outstanding,  the  Company  shall  take all  action
necessary  to at all times have  authorized,  and  reserved  for the  purpose of
issuance, no less than a number of shares of Common Stock equal to the number of
shares of Common Stock that are not  currently  issued or reserved for issuance;
provided,  however,  upon the Company filing the Charter Amendment,  the Company
shall take all action  necessary to at all times have  authorized,  and reserved
for the  purpose  of  issuance,  free of  preemptive  rights  and other  similar
contractual rights of stockholders,  a number of shares of Common Stock equal to
one  hundred  fifty  percent  (150%) of the number of shares of Common  Stock as
shall from time to time be  sufficient  to effect the  conversion  of all of the
Preferred Shares and exercise of the Warrants then outstanding.

            Section 3.13 Transfer  Agent  Instructions.  The Company shall issue
irrevocable  instructions  to its transfer  agent,  and any subsequent  transfer
agent,  to issue  certificates,  registered in the name of each Purchaser or its
respective nominee(s),  for the Conversion Shares and the Warrant Shares in such
amounts as  specified  from time to time by each  Purchaser  to the Company upon
conversion  of the  Preferred  Shares or exercise of the Warrants in the form of
Exhibit G attached hereto (the "Irrevocable Transfer Agent Instructions"). Prior
to  registration  of the  Conversion  Shares and the  Warrant  Shares  under the
Securities  Act,  all  such  certificates  shall  bear  the  restrictive  legend
specified  in  Section  5.1 of this  Agreement.  The  Company  warrants  that no
instruction other than the Irrevocable  Transfer Agent Instructions  referred to
in this Section 3.13 will be given by the Company to its transfer agent and that
the Shares shall  otherwise be freely  transferable  on the books and records of
the Company as and to the extent provided in this Agreement and the Registration
Rights  Agreement.  If a  Purchaser  provides  the  Company  with an  opinion of
counsel,  in a generally  acceptable  form,  to the effect  that a public  sale,
assignment  or  transfer of all or some of such  Purchaser's  Shares may be made
without   registration  under  the  Securities  Act  and  any  applicable  state
securities laws or the Purchaser provides the Company with reasonable assurances
that such  Shares  can be sold  pursuant  to Rule 144 and any  applicable  state
securities laws within the limitations of Rule 144, the Company shall permit the
transfer,  and, in the case of the  Conversion  Shares and the  Warrant  Shares,
promptly  instruct its transfer agent to issue one or more  certificates in such
name and in such  denominations  as specified by such  Purchaser and without any
restrictive  legend.  The  Company  acknowledges  that  a  breach  by it of  its
obligations  under  this  Section  3.13  will  cause  irreparable  harm  to  the
Purchasers by vitiating the intent and purpose of the  transaction  contemplated
hereby.  Accordingly,  the  Company  acknowledges  that the  remedy at law for a
breach of its

                                       18
<PAGE>

obligations  under this Section 3.13 will be inadequate and agrees, in the event
of a breach  or  threatened  breach by the  Company  of the  provisions  of this
Section 3.13,  that the Purchasers  shall be entitled,  in addition to all other
available  remedies,  to an order and/or  injunction  restraining any breach and
requiring  immediate  issuance and  transfer,  without the  necessity of showing
economic loss and without any bond or other security being required.

            Section 3.14 Disposition of Assets.  So long as any Preferred Shares
remain outstanding,  neither the Company nor any Subsidiary shall sell, transfer
or otherwise dispose of substantially  all of its properties,  assets and rights
including,  without limitation,  its software and intellectual  property, to any
person except for sales to customers in the ordinary  course of business or with
the prior written  consent of the holders of a majority of the Preferred  Shares
then outstanding.

            Section 3.15  Disclosure of  Transaction.  The Company shall issue a
press release  describing  the material terms of the  transactions  contemplated
hereby (the "Press Release") as soon as practicable  after the Closing but in no
event later than 9:00 A.M.  Eastern Time on the first  Trading Day following the
Closing.  The Company  shall also file with the  Commission a Current  Report on
Form 8-K (the "Form 8-K")  describing  the  material  terms of the  transactions
contemplated  hereby (and  attaching  as exhibits  thereto this  Agreement,  the
Registration  Rights  Agreement,  the  Certificate of  Designation,  the Lock-Up
Agreement,  the form of each series of Warrant and the Press Release) as soon as
practicable  following  the  Closing  Date but in no event  more  than  four (4)
Trading Days following the Closing Date,  which Press Release and Form 8-K shall
be subject to prior review and comment by the  Purchasers.  "Trading  Day" means
any day  during  which  the OTC  Bulletin  Board (or  other  quotation  venue or
principal  exchange  on which  the  Common  Stock is  traded)  shall be open for
trading.

            Section  3.16  Disclosure  of  Material  Information.   The  Company
covenants  and agrees that neither it nor any other person  acting on its behalf
has  provided or will  provide any  Purchaser  or its agents or counsel with any
information  that  the  Company   believes   constitutes   material   non-public
information  (other than with respect to the  transactions  contemplated by this
Agreement),  unless prior thereto such  Purchaser  shall have executed a written
agreement regarding the confidentiality and use of such information. The Company
understands  and confirms that each Purchaser  shall be relying on the foregoing
representations  in effecting  transactions  in  securities  of the Company.  By
executing this Agreement, each Purchaser agrees to keep all information provided
by the Company  confidential  (the  "Confidential  Information") and to only use
such  information in connection with  evaluating a purchase of the Shares.  Each
Purchaser shall destroy or return all Confidential  Information  provided by the
Company upon Company's request.

            Section  3.17 Pledge of  Securities.  The Company  acknowledges  and
agrees that the Shares may be pledged by a Purchaser in  connection  with a bona
fide margin agreement or other loan or financing  arrangement that is secured by
the  Common  Stock.  The  pledge  of  Common  Stock  shall not be deemed to be a
transfer,  sale or  assignment of the Common Stock  hereunder,  and no Purchaser
effecting a pledge of Common Stock shall be required to provide the Company with
any notice  thereof or otherwise  make any  delivery to the Company  pursuant to
this Agreement or any other Transaction Document;  provided that a Purchaser and
its pledgee shall be required to comply with the  provisions of Article V hereof
in order to  effect a sale,

                                       19
<PAGE>

transfer or  assignment  of Common  Stock to such  pledgee.  At the  Purchasers'
expense,  the Company hereby agrees to execute and deliver such documentation as
a pledgee of the Common Stock may reasonably request in connection with a pledge
of the Common Stock to such pledgee by a Purchaser.

            Section 3.18 Form SB-2 Eligibility.  The Company currently meets the
"registrant  eligibility"  requirements set forth in the general instructions to
Form SB-2 and the  Company  shall file all  reports  required to be filed by the
Company with the Commission in a timely manner.

            Section 3.19 Lock-Up Agreement.  The persons listed on Schedule 3.20
attached  hereto  shall be  subject  to the  terms and  provisions  of a lock-up
agreement  in  substantially   the  form  as  Exhibit  E  hereto  (the  "Lock-Up
Agreement"),  which shall  provide the manner in which such  persons  will sell,
transfer or dispose of their shares of Common Stock.

            Section 3.20 Investor  Relations Firm. The company will agree to set
aside a minimum of  $250,000  to be used  exclusively  for  investor  relations,
including but not limited to hiring an Investor Relations firm within 30 days of
closing.

            Section 3.21 Reverse Split of Outstanding Shares.  Immediately prior
to the consummation of the transactions  contemplated  hereby, the Company shall
effect a 4-to-1 reverse stock split  bringing  reducing its  outstanding  shares
from 5,584,000  shares of Common Stock to 1,396,000  shares of Common Stock (the
"Reverse Split").

            Section 3.22 Authorization of Preferred Shares. Immediately prior to
the consummation of the transactions contemplated hereby, the Company shall file
an amendment to the Articles with the Nevada Secretary of State to authorize the
issuance  of  the  Preferred  Shares  (the  "Preferred  Shares  Authorization"),
consistent  with the terms set forth in the  Certificate  of  Designation of the
Relative Rights and  Preferences of the Series A Convertible  Preferred Stock of
Dentalserv.com (the "Certificate of Designations") being executed by the Company
concurrent with the execution of this Agreement.

            Section 3.23  Increase in Authorized  Shares.  Not later than ninety
(90) days following the Closing Date, the Company shall file an amendment to the
Articles with the Nevada  Secretary of State to effect an increase in the number
of its  authorized  shares  of  Common  Stock to at least a number  of shares of
Common  Stock  sufficient  to reserve one hundred  fifty  percent  (150%) of the
number of shares of Common  Stock as shall  from time to time be  sufficient  to
effect  the  conversion  of all of the  Preferred  Shares  and  exercise  of the
Warrants  then  outstanding  (the  "Charter  Amendment").  In the event that the
Authorized  Share  Increase  has not  been  effected  within  ninety  (90)  days
following the Closing Date, the term of each series of Warrant  issued  pursuant
to this Agreement shall be  automatically  extended for a period of one (1) year
(and the Company shall promptly issue to each Purchaser new Warrants  evidencing
the extension of such Warrant term) and each  Purchaser  shall have the right to
redeem any Preferred  Shares then held by it in accordance with the terms of the
Certificate of Designation.

            Section 3.24 Subsequent Financings.

                                       20
<PAGE>

            (a) For a period of one (1) year following the effective date of the
Registration  Statement (as defined in the Registration  Rights Agreement),  the
Company  covenants and agrees to promptly notify in writing (a "Rights  Notice")
the  Purchasers of the terms and conditions of any proposed offer or sale to, or
exchange with (or other type of distribution  to) any third party (a "Subsequent
Financing"),  of  Common  Stock or any debt or  equity  securities  convertible,
exercisable or exchangeable into Common Stock. The Rights Notice shall describe,
in reasonable detail, the proposed  Subsequent  Financing,  the proposed closing
date of the  Subsequent  Financing,  which  shall  be no  earlier  than ten (10)
Trading  Days  from the date of the  Rights  Notice,  and all of the  terms  and
conditions  thereof.  The Rights Notice shall  provide each  Purchaser an option
(the "Rights Option") during the ten (10) Trading Days following delivery of the
Rights Notice (the "Option Period") to inform the Company whether such Purchaser
will  purchase up to its pro rata portion of all or a portion of the  securities
being  offered in such  Subsequent  Financing  on the same,  absolute  terms and
conditions as contemplated by such Subsequent Financing. If any Purchaser elects
not to  participate  in such  Subsequent  Financing,  the other  Purchasers  may
participate on a pro-rata basis. For purposes of this Section, all references to
"pro rata" means,  for any Purchaser  electing to participate in such Subsequent
Financing,  the  percentage  obtained  by dividing  (x) the number of  Preferred
Shares purchased by such Purchaser at the Closing by (y) the total number of all
of the Preferred Shares purchased by all of the participating  Purchasers at the
Closing. If the Company does not receive notice of exercise of the Rights Option
from any or all of Purchasers  within the Option Period,  the Company shall have
the right to close the Subsequent  Financing on or before the scheduled  closing
date set forth in the  Rights  Notice (or within  thirty  (30) days  thereafter)
without the participation of any or all of such Purchasers; provided that all of
the material  terms and conditions of the closing are the same as those provided
to  the  Purchasers  in  the  Rights  Notice.  If the  closing  of the  proposed
Subsequent  Financing does not occur on the scheduled  closing date set forth in
the Rights  Notice (or within thirty (30) days  thereafter),  any closing of the
contemplated  Subsequent  Financing or any other  Subsequent  Financing shall be
subject to all of the  provisions of this Section  3.23(a),  including,  without
limitation,  the delivery of a new Rights Notice. The provisions of this Section
3.23(a) shall not apply to issuances of securities in a Permitted Financing.

            (b) For  purposes  of this  Agreement,  a  Permitted  Financing  (as
defined  hereinafter)  shall  not  be  considered  a  Subsequent  Financing.   A
"Permitted  Financing" shall mean (i) securities issued (other than for cash) in
connection  with a merger,  acquisition,  or  consolidation,  or the issuance of
securities  in  connection  with the  purchase  of patent or  related  rights to
medical equipment or devices, (ii) warrants for up to 3,000,000 shares of Common
Stock of the  Company in  connection  with an  employee  stock  option  program,
incentive stock option program,  or other  qualified or  non-qualified  employee
benefit plan (an "ESOP") to be  established  concurrent  with the closing of the
Merger (as defined in Section 4.2(c)  hereof),  priced at $1.81 per share, to be
issued to the current management of Medpro Safety Products,  Inc. ("Medpro") and
the future  management  of the  Company  (the  "ESOP  Warrants"),  (iii)  68,036
warrants,  priced at $1.99,  to be issued to Chrystal  Research  (the  "Chrystal
Research Warrants"),  (iv) 533,458 warrants, priced at $1.81, to be issued to SC
Capital Partners,  LLC (the "SC Capital  Warrants"),  (v) Common Stock issued or
the  issuance  or grants of options to  purchase  Common  Stock  pursuant to the
Company's  stock option plans and employee stock  purchase plans  outstanding as
they exist on the date of this  Agreement,  and (vi) any warrants  issued to the

                                       21
<PAGE>

placement  agent,  any investor  relations  firm,  and their  designees  for the
transactions contemplated by the Purchase Agreement.

            (c) For a period of two (2) years  following the Closing  Date,  the
Company  shall be  prohibited  from  effecting or entering  into an agreement to
effect any Subsequent  Financing involving a "Variable Rate Transaction" without
the prior  written  consent of the holders of 75% of the  Preferred  Shares then
outstanding;  provided,  however,  that the  number  of  Preferred  Shares  then
outstanding is greater than two hundred thousand  (200,000).  The term "Variable
Rate Transaction"  shall mean a transaction in which the Company issues or sells
(i) any debt or equity  securities  that are convertible  into,  exchangeable or
exercisable  for,  or include the right to receive  additional  shares of Common
Stock either (A) at a conversion,  exercise or exchange rate or other price that
is based upon and/or  varies with the trading  prices of or  quotations  for the
shares of Common  Stock at any time after the  initial  issuance of such debt or
equity securities, or (B) with a conversion,  exercise or exchange price that is
subject to being reset at some  future  date after the initial  issuance of such
debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly  related to the business of the Company or the market for
the Common Stock (other than  customary  anti-dilution  features) or (ii) enters
into any  agreement,  including,  but not  limited to, an equity line of credit,
whereby the Company may sell securities at a future determined price.

            (d) For the period  commencing on the Closing Date and ending on the
date that is one hundred  eighty (180) days  following the effective date of the
Registration  Statement,  the Company shall not file any registration  statement
under the  Securities Act without the prior written  consent of the  Purchasers,
other than the  Registration  Statement.  Notwithstanding  the  foregoing,  this
Section 3.23 shall not be applicable as to any  securities  issued in connection
with (i) any future strategic  acquisitions which are approved in writing by the
Purchasers, such approval not to be unreasonably withheld, (ii) the consummation
or operation of the agency  agreement  between  Medpro and SPGF, LLC , (iii) the
ESOP  Warrants,  (iv) the  Chrystal  Research  Warrants,  or (v) the SC  Capital
Warrants.

                                   ARTICLE IV

                                   CONDITIONS

            Section 4.1 Conditions Precedent to the Obligation of the Company to
Sell the Shares.  The obligation  hereunder of the Company to issue and sell the
Preferred  Shares  and  the  Warrants  to  the  Purchasers  is  subject  to  the
satisfaction or waiver, at or before the Closing,  of each of the conditions set
forth below.  These  conditions  are for the  Company's  sole benefit and may be
waived by the Company at any time in its sole  discretion.

            (a) Accuracy of Each Purchaser's Representations and Warranties. The
representations  and warranties of each  Purchaser  shall be true and correct in
all  material  respects as of the date when made and as of the  Closing  Date as
though made at that time,  except for  representations  and warranties  that are
expressly made as of a particular  date,  which shall be true and correct in all
material respects as of such date.

                                       22
<PAGE>

            (b)  Performance  by  the  Purchasers.  Each  Purchaser  shall  have
performed, satisfied and complied in all respects with all covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied
with by such Purchaser at or prior to the Closing.

            (c) No Injunction.  No statute, rule,  regulation,  executive order,
decree,  ruling or injunction shall have been enacted,  entered,  promulgated or
endorsed by any court or governmental  authority of competent jurisdiction which
prohibits  the  consummation  of any of the  transactions  contemplated  by this
Agreement.

            (d) Delivery of Purchase Price. The Purchase Price for the Preferred
Shares and  Warrants  has been  delivered  to the escrow  agent  pursuant to the
Escrow Agreement.

            (e) Delivery of Transaction  Documents.  The  Transaction  Documents
shall have been duly executed and delivered by the Purchasers  and, with respect
to the  Escrow  Agreement,  the  escrow  agent,  to  the  Company.

            Section 4.2 Conditions Precedent to the Obligation of the Purchasers
to Purchase the Shares.  The  obligation  hereunder of each Purchaser to acquire
and pay for the Preferred Shares and the Warrants is subject to the satisfaction
or waiver, at or before the Closing,  of each of the conditions set forth below.
These conditions are for each Purchaser's sole benefit and may be waived by such
Purchaser at any time in its sole discretion.

            (a) Accuracy of the Company's  Representations and Warranties.  Each
of the  representations  and warranties of the Company in this Agreement and the
Registration  Rights  Agreement  shall be true and correct in all respects as of
the date  when  made and as of the  Closing  Date as  though  made at that  time
(except for  representations  and  warranties  that are  expressly  made as of a
particular  date),  which shall be true and  correct in all  respects as of such
date.

            (b)  Performance by the Company.  The Company shall have  performed,
satisfied  and  complied in all  respects  with all  covenants,  agreements  and
conditions  required by this  Agreement to be  performed,  satisfied or complied
with by the Company at or prior to the Closing.

            (c) Merger with Medpro.  The Company  shall have  completed a merger
with and into Medpro,  with the Company being the surviving  corporation thereof
(the  "Merger").

            (d) No Injunction.  No statute, rule,  regulation,  executive order,
decree,  ruling or injunction shall have been enacted,  entered,  promulgated or
endorsed by any court or governmental  authority of competent jurisdiction which
prohibits  the  consummation  of any of the  transactions  contemplated  by this
Agreement.

            (e) No  Proceedings  or  Litigation.  No action,  suit or proceeding
before any arbitrator or any  governmental  authority shall have been commenced,
and no investigation  by any governmental  authority shall have been threatened,
against the Company or any  subsidiary,

                                       23
<PAGE>

or any of the officers, directors or affiliates of the Company or any subsidiary
seeking to restrain,  prevent or change the  transactions  contemplated  by this
Agreement, or seeking damages in connection with such transactions.

            (f) Certificate of Designation of Rights and  Preferences.  Prior to
the Closing,  the  Certificate  of Designation in the form of Exhibit B attached
hereto shall have been filed with the Secretary of State of Nevada.

            (g) Opinion of Counsel,  Etc. At the Closing,  the Purchasers  shall
have  received  an  opinion of  counsel  to the  Company,  dated the date of the
Closing,  in the form of  Exhibit  H hereto,  and such  other  certificates  and
documents as the Purchasers or its counsel shall reasonably  require incident to
the Closing.

            (h) Registration Rights Agreement. At the Closing, the Company shall
have executed and delivered the Registration Rights Agreement to each Purchaser.

            (i)  Certificates.  The Company shall have executed and delivered to
the Purchasers the certificates  (in such  denominations as such Purchaser shall
request)  for the  Preferred  Shares and the  Warrants  being  acquired  by such
Purchaser  at the  Closing  (in  such  denominations  as  such  Purchaser  shall
request).

            (j)  Resolutions.  The Board of Directors of the Company  shall have
adopted  resolutions  consistent with Section 2.1(b) hereof in a form reasonably
acceptable to such Purchaser (the "Resolutions").

            (k) Reservation of Shares. As of the Closing Date, the Company shall
have reserved out of its  authorized and unissued  Common Stock,  solely for the
purpose of effecting the conversion of the Preferred  Shares and the exercise of
the  Warrants,  a number of shares of Common  Stock equal to one  hundred  fifty
percent  (150%) of the  aggregate  number of  Conversion  Shares  issuable  upon
conversion  of the  Preferred  Shares  issued or to be issued  pursuant  to this
Agreement and the number of Warrant Shares  issuable upon exercise of the number
of Warrants issued or to be issued pursuant to this Agreement.

            (l)  Transfer  Agent  Instructions.  As of  the  Closing  Date,  the
Irrevocable  Transfer  Agent  Instructions,  in the form of  Exhibit G  attached
hereto,  shall  have  been  delivered  to and  acknowledged  in  writing  by the
Company's transfer agent.

            (m) Lock-Up Agreement. As of the Closing Date, the persons listed on
Schedule  3.20 hereto shall have  delivered to the  Purchasers a fully  executed
Lock-Up  Agreement  in the form of Exhibit E attached  hereto.

            (n)  Secretary's  Certificate.  The Company shall have  delivered to
such  Purchaser a secretary's  certificate,  dated as of the Closing Date, as to
(i) the Resolutions,  (ii) the Articles,  (iii) the Bylaws, (iv) the Certificate
of  Designation,  each as in effect at the Closing,  and (iv) the  authority and
incumbency of the officers of the Company  executing the  Transaction

                                       24
<PAGE>

Documents  and any other  documents  required  to be executed  or  delivered  in
connection therewith.

            (o) Officer's  Certificate.  The Company shall have delivered to the
Purchasers a certificate of an executive officer of the Company, dated as of the
Closing  Date,  confirming  the  accuracy  of  the  Company's   representations,
warranties and covenants as of the Closing Date and confirming the compliance by
the Company with the  conditions  precedent  set forth in this Section 4.2 as of
the Closing Date.

            (p) Voting Agreements.  The Purchasers shall have received copies of
executed voting agreements of the Company's  stockholders,  in substantially the
form of Exhibit I hereto,  evidencing  such  stockholder's  agreement to vote in
favor of the Merger,  the Reverse Split, the Charter Amendment and the Preferred
Shares Authorization.

            (q) Escrow  Agreement.  At the  Closing,  the Company and the escrow
agent shall have  executed  and  delivered  the Escrow  Agreement in the form of
Exhibit F attached hereto to each Purchaser.

            (r) Material  Adverse Effect.  No Material Adverse Effect shall have
occurred at or before the Closing Date.

                                   ARTICLE V

                            Stock Certificate Legend

            Section 5.1 Legend.  Each  certificate  representing  the  Preferred
Shares and the Warrants, and, if appropriate,  securities issued upon conversion
thereof,  shall be stamped or otherwise imprinted with a legend substantially in
the  following  form (in  addition to any legend  required by  applicable  state
securities or "blue sky" laws):

            THE  SECURITIES   REPRESENTED  BY  THIS  CERTIFICATE  (THE
            "SECURITIES")   HAVE  NOT  BEEN   REGISTERED   UNDER   THE
            SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES  ACT")
            OR  ANY  STATE  SECURITIES  LAWS  AND  MAY  NOT  BE  SOLD,
            TRANSFERRED  OR  OTHERWISE  DISPOSED OF UNLESS  REGISTERED
            UNDER  THE  SECURITIES  ACT  AND  UNDER  APPLICABLE  STATE
            SECURITIES LAWS OR  DENTALSERV.COM  SHALL HAVE RECEIVED AN
            OPINION OF COUNSEL THAT  REGISTRATION  OF SUCH  SECURITIES
            UNDER  THE  SECURITIES  ACT AND UNDER  THE  PROVISIONS  OF
            APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

            The Company agrees to reissue  certificates  representing any of the
Conversion Shares and the Warrant Shares,  without the legend set forth above if
at such time, prior to making any transfer of any such  securities,  such holder
thereof shall give written notice to the Company describing the manner and terms
of such  transfer  and  removal as the  Company  may  reasonably  request.  Such
proposed  transfer  and removal will not be effected  until:  (a) either (i) the

                                       25
<PAGE>

Company  has  received  an  opinion of counsel  reasonably  satisfactory  to the
Company,  to the effect that the  registration  of the Conversion  Shares or the
Warrant Shares under the Securities Act or any applicable  state securities laws
is not required in connection with such proposed  transfer,  (ii) a registration
statement  under the Securities Act covering such proposed  disposition has been
filed by the Company  with the  Commission  and has become  effective  under the
Securities  Act,  (iii) the  Company  has  received  other  evidence  reasonably
satisfactory to the Company that such registration and  qualification  under the
Securities Act and state  securities  laws are not required,  or (iv) the holder
provides the Company with  reasonable  assurances that such security can be sold
pursuant to Rule 144 under the  Securities  Act and  pursuant to any  applicable
state securities laws; and (b) either (i) the Company has received an opinion of
counsel reasonably  satisfactory to the Company, to the effect that registration
or  qualification  under the  securities  or "blue sky" laws of any state is not
required in connection with such proposed  disposition,  or (ii) compliance with
applicable  state  securities  or "blue sky" laws has been  effected  or a valid
exemption  exists with  respect  thereto.  The Company  will respond to any such
notice from a holder within five (5) business  days. In the case of any proposed
transfer  under this Section 5.1,  the Company  will use  reasonable  efforts to
comply with any such applicable  state  securities or "blue sky" laws, but shall
in no event be required,  (x) to qualify to do business in any state where it is
not then  qualified,  (y) to take any action that would  subject it to tax or to
the general service of process in any state where it is not then subject, or (z)
to  comply  with  state  securities  or "blue  sky"  laws of any state for which
registration by coordination is unavailable to the Company.  The restrictions on
transfer  contained  in this Section 5.1 shall be in addition to, and not by way
of  limitation  of, any other  restrictions  on transfer  contained in any other
section of this Agreement.  Whenever a certificate  representing  the Conversion
Shares or  Warrant  Shares is  required  to be issued to a  Purchaser  without a
legend, in lieu of delivering physical certificates  representing the Conversion
Shares or Warrant  Shares  (provided  that a  registration  statement  under the
Securities  Act  providing for the resale of the Warrant  Shares and  Conversion
Shares  is then in  effect),  the  Company  shall  cause its  transfer  agent to
electronically  transmit the Conversion  Shares or Warrant Shares to a Purchaser
by crediting the account of such Purchaser or such Purchaser's Prime Broker with
the  Depository  Trust  Company  ("DTC")  through its Deposit  Withdrawal  Agent
Commission  ("DWAC") system (to the extent not inconsistent  with any provisions
of this Agreement).

                                   ARTICLE VI

                                 Indemnification

            Section 6.1 General  Indemnity.  The Company agrees to indemnify and
hold  harmless  the  Purchasers  (and  their  respective  directors,   officers,
managers, partners, members,  shareholders,  affiliates,  agents, successors and
assigns) from and against any and all losses, liabilities,  deficiencies, costs,
damages and expenses (including, without limitation, reasonable attorneys' fees,
charges  and  disbursements)  incurred  by the  Purchasers  as a  result  of any
inaccuracy in or breach of the representations,  warranties or covenants made by
the Company herein. Each Purchaser severally but not jointly agrees to indemnify
and hold harmless the Company and its directors,  officers,  affiliates, agents,
successors  and  assigns  from  and  against  any and all  losses,  liabilities,
deficiencies,  costs,  damages  and  expenses  (including,  without  limitation,
reasonable attorneys' fees, charges and disbursements) incurred by the Company a

                                       26
<PAGE>

result of any  inaccuracy  in or breach of the  representations,  warranties  or
covenants made by such Purchaser herein. The maximum aggregate liability of each
Purchaser  pursuant to its  indemnification  obligations  under this  Article VI
shall not  exceed  the  portion of the  Purchase  Price  paid by such  Purchaser
hereunder.

            Section  6.2  Indemnification   Procedure.  Any  party  entitled  to
indemnification under this Article VI (an "indemnified party") will give written
notice  to the  indemnifying  party of any  matters  giving  rise to a claim for
indemnification;   provided,   that  the  failure  of  any  party   entitled  to
indemnification  hereunder  to give notice as provided  herein shall not relieve
the  indemnifying  party of its obligations  under this Article VI except to the
extent that the  indemnifying  party is actually  prejudiced  by such failure to
give  notice.  In case any  action,  proceeding  or claim is brought  against an
indemnified party in respect of which  indemnification is sought hereunder,  the
indemnifying  party  shall be  entitled  to  participate  in and,  unless in the
reasonable  judgment of the indemnified  party a conflict of interest between it
and the indemnifying party may exist with respect of such action,  proceeding or
claim, to assume the defense thereof with counsel reasonably satisfactory to the
indemnified  party.  In  the  event  that  the  indemnifying  party  advises  an
indemnified  party  that  it  will  contest  such a  claim  for  indemnification
hereunder,  or fails,  within thirty (30) days of receipt of any indemnification
notice to notify, in writing,  such person of its election to defend,  settle or
compromise,  at its sole cost and expense,  any action,  proceeding or claim (or
discontinues its defense at any time after it commences such defense),  then the
indemnified party may, at its option,  defend, settle or otherwise compromise or
pay such action or claim. In any event,  unless and until the indemnifying party
elects in writing to assume  and does so assume the  defense of any such  claim,
proceeding or action, the indemnified  party's costs and expenses arising out of
the defense,  settlement or  compromise of any such action,  claim or proceeding
shall be losses subject to  indemnification  hereunder.  The  indemnified  party
shall  cooperate  fully  with  the  indemnifying  party in  connection  with any
negotiation or defense of any such action or claim by the indemnifying party and
shall furnish to the indemnifying party all information  reasonably available to
the indemnified  party which relates to such action or claim.  The  indemnifying
party shall keep the  indemnified  party  fully  apprised at all times as to the
status of the defense or any settlement  negotiations  with respect thereto.  If
the  indemnifying  party  elects to defend  any such  action or claim,  then the
indemnified  party shall be entitled to participate in such defense with counsel
of its choice at its sole cost and expense.  The indemnifying party shall not be
liable for any settlement of any action,  claim or proceeding  effected  without
its prior written  consent.  Notwithstanding  anything in this Article VI to the
contrary,  the  indemnifying  party shall not,  without the indemnified  party's
prior written consent, settle or compromise any claim or consent to entry of any
judgment  in  respect  thereof  which  imposes  any  future  obligation  on  the
indemnified party or which does not include,  as an unconditional  term thereof,
the  giving by the  claimant  or the  plaintiff  to the  indemnified  party of a
release  from all  liability  in  respect  of such  claim.  The  indemnification
required  by this  Article VI shall be made by  periodic  payments of the amount
thereof  during the course of  investigation  or defense,  as and when bills are
received or expense,  loss,  damage or  liability  is  incurred,  so long as the
indemnified party  irrevocably  agrees to refund such moneys if it is ultimately
determined by a court of competent jurisdiction that such party was not entitled
to  indemnification.  The  indemnity  agreements  contained  herein  shall be in
addition to (a) any cause of action or similar rights of the  indemnified  party
against

                                       27
<PAGE>

the indemnifying party or others, and (b) any liabilities the indemnifying party
may be subject to pursuant to the law.

                                  ARTICLE VII

                                  Miscellaneous

            Section 7.1 Fees and Expenses. Except as otherwise set forth in this
Agreement and the other Transaction Documents, each party shall pay the fees and
expenses of its advisors,  counsel,  accountants and other experts,  if any, and
all  other  expenses,  incurred  by  such  party  incident  to the  negotiation,
preparation,  execution,  delivery and performance of this  Agreement,  provided
that the Company shall pay all actual  attorneys'  fees and expenses  (including
disbursements  and  out-of-pocket   expenses)  incurred  by  the  Purchasers  in
connection with (i) the preparation, negotiation, execution and delivery of this
Agreement and the other Transaction Documents and the transactions  contemplated
thereunder,  which  payment  shall be made at the  Closing  and shall not exceed
$40,000 (plus  disbursements  and out-of-pocket  expenses),  (ii) the filing and
declaration of effectiveness by the Commission of the Registration Statement and
(iii) any amendments,  modifications  or waivers of this Agreement or any of the
other  Transaction  Documents.  The Company  shall also pay up to $30,000 to the
Purchasers at the Closing in connection  with all  reasonable and documented due
diligence  expenses  incurred  by the  Purchasers  and all  reasonable  fees and
expenses  incurred by the Purchasers in connection  with the enforcement of this
Agreement  or  any  of  the  other  Transaction  Documents,  including,  without
limitation, all reasonable attorneys' fees and expenses.

            Section 7.2 Specific Enforcement,  Consent to Jurisdiction.

            (a) The  Company  and the  Purchasers  acknowledge  and  agree  that
irreparable  damage would occur in the event that any of the  provisions of this
Agreement or the other  Transaction  Documents  were not performed in accordance
with their specific terms or were otherwise  breached.  It is accordingly agreed
that the parties shall be entitled to an injunction or injunctions to prevent or
cure breaches of the  provisions of this  Agreement or the  Registration  Rights
Agreement  and to  enforce  specifically  the  terms  and  provisions  hereof or
thereof,  this being in addition to any other remedy to which any of them may be
entitled by law or equity.

            (b) Each of the Company and the  Purchasers  (i) hereby  irrevocably
submits to the  jurisdiction  of the United States District Court sitting in the
Southern District of New York and the courts of the State of New York located in
New York county for the purposes of any suit,  action or proceeding  arising out
of or relating to this  Agreement or any of the other  Transaction  Documents or
the  transactions  contemplated  hereby or thereby and (ii) hereby  waives,  and
agrees not to assert in any such suit,  action or proceeding,  any claim that it
is not  personally  subject to the  jurisdiction  of such court,  that the suit,
action or  proceeding is brought in an  inconvenient  forum or that the venue of
the  suit,  action  or  proceeding  is  improper.  Each of the  Company  and the
Purchasers  consents  to  process  being  served  in any such  suit,  action  or
proceeding  by mailing a copy thereof to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute
good and  sufficient  service of process  and  notice  thereof.  Nothing in this
Section 7.2 shall affect or limit any right to serve process in any other manner
permitted by law.

                                       28
<PAGE>

            Section 7.3 Entire  Agreement;  Amendment.  This  Agreement  and the
Transaction  Documents  contains the entire  understanding  and agreement of the
parties with respect to the matters  covered hereby and,  except as specifically
set forth herein or in the Transaction Documents, neither the Company nor any of
the Purchasers makes any representations, warranty, covenant or undertaking with
respect  to such  matters  and  they  supersede  all  prior  understandings  and
agreements with respect to said subject matter,  all of which are merged herein.
No provision of this  Agreement may be waived or amended other than by a written
instrument  signed  by the  Company  and the  holders  of at least  seventy-five
percent (75%) of the Preferred Shares then outstanding;  provided, however, that
the number of  Preferred  Shares then  outstanding  is greater  than two hundred
thousand  (200,000),  and no  provision  hereof may be waived other than by an a
written  instrument  signed by the party  against whom  enforcement  of any such
amendment  or waiver is sought.  No such  amendment  shall be  effective  to the
extent that it applies to less than all of the holders of the  Preferred  Shares
then  outstanding.  No  consideration  shall be offered or paid to any person to
amend or  consent to a waiver or  modification  of any  provision  of any of the
Transaction  Documents  unless the same  consideration is also offered to all of
the parties to the Transaction  Documents or holders of Preferred Shares, as the
case may be.

            Section 7.4 Notices. Any notice,  demand,  request,  waiver or other
communication  required or permitted to be given  hereunder  shall be in writing
and shall be effective (a) upon hand delivery by telex (with correct answer back
received),  telecopy or facsimile at the address or number  designated below (if
delivered on a business day during normal business hours where such notice is to
be received),  or the first  business day following  such delivery (if delivered
other than on a business day during normal  business  hours where such notice is
to be received) or (b) on the second  business day following the date of mailing
by express courier service,  fully prepaid,  addressed to such address,  or upon
actual receipt of such mailing,  whichever shall first occur.  The addresses for
such communications shall be:

                  If to the Company:     Dentalserv.com
                                         20 W. 55th Street
                                         5th Street
                                         New York, NY 10010
                                         Tel. No.:  (212) 849-8248
                                         Fax No.: (212) 867-1416

                  with copies to:        Law Office of Eugene Michael Kennedy
                                         517 SW First Avenue
                                         Ft. Lauderdale, FL 33301
                                         Attention: Eugene Michael Kennedy, Esq.
                                         Tel. No.:  (954) 524-4155
                                         Fax No.:  (954) 525-4169

                  If to  any  Purchaser: At  the address of such Purchaser
                                         set forth  on  Exhibit  A to this
                                         Agreement,   with  copies  to
                                         Purchaser's  counsel  as  set
                                         forth  on  Exhibit  A  or  as

                                       29
<PAGE>

                                         specified  in writing by such
                                         Purchaser with copies to:

                                         Lord Bissell & Brook LLP
                                         885 Third Avenue, 26th Floor
                                         New York, New York 10022
                                         Attention:  Corey N. Martin, Esq.
                                         Tel No.:  (212) 812-8314
                                         Fax No.:  (212) 812-8374

            Any  party  hereto  may from time to time  change  its  address  for
notices by giving at least ten (10) days written notice of such changed  address
to the other party hereto.

            Section 7.5  Waivers.  No waiver by either party of any default with
respect to any provision,  condition or  requirement of this Agreement  shall be
deemed  to be a  continuing  waiver  in the  future  or a  waiver  of any  other
provisions,  condition or requirement hereof, nor shall any delay or omission of
any party to exercise any right  hereunder in any manner  impair the exercise of
any such right accruing to it thereafter.

            Section 7.6 Headings.  The article,  section and subsection headings
in this  Agreement are for  convenience  only and shall not constitute a part of
this  Agreement for any other purpose and shall not be deemed to limit or affect
any of the provisions hereof.

            Section 7.7 Successors and Assigns.  This Agreement shall be binding
upon and inure to the benefit of the parties and their  successors  and assigns.

            Section 7.8 No Third Party Beneficiaries. This Agreement is intended
for the benefit of the parties hereto and their respective  permitted successors
and  assigns  and is not for the  benefit  of, nor may any  provision  hereof be
enforced by, any other person.

            Section 7.9 Governing Law. This  Agreement  shall be governed by and
construed in accordance with the internal laws of the State of New York, without
giving  effect to any of the conflicts of law  principles  which would result in
the application of the substantive law of another  jurisdiction.  This Agreement
shall not be  interpreted or construed  with any  presumption  against the party
causing this Agreement to be drafted.

            Section 7.10  Survival.  The  representations  and warranties of the
Company and the Purchasers  shall survive the execution and delivery  hereof and
the Closings hereunder.

            Section 7.11  Counterparts.  This  Agreement  may be executed in any
number of counterparts,  each of which when so executed shall be deemed to be an
original  and, all of which taken  together  shall  constitute  one and the same
Agreement and shall become effective when  counterparts have been signed by each
party and delivered to the other parties  hereto,  it being  understood that all
parties need not sign the same  counterpart.  In the event that any signature is
delivered  by  facsimile   transmission  or  scanned  electronic  mail  (e-mail)
attachment,  such signature shall create a valid binding obligation of the party
executing (or on whose behalf such

                                       30
<PAGE>

signature  is  executed)  the same  with the same  force  and  effect as if such
facsimile or scanned signature were the original thereof.

            Section  7.12  Publicity.  The  Company  agrees  that  it  will  not
disclose,  and will not  include  in any  public  announcement,  the name of the
Purchasers  without  the  consent  of  the  Purchasers  unless  and  until  such
disclosure  is required by law or applicable  regulation or as required  herein,
and then only to the extent of such requirement.

            Section 7.13 Severability.  The provisions of this Agreement and the
Transaction  Documents  are  severable  and,  in the  event  that  any  court of
competent jurisdiction shall determine that any one or more of the provisions or
part of the provisions contained in this Agreement or the Transaction  Documents
shall,  for any reason,  be held to be invalid,  illegal or unenforceable in any
respect,  such invalidity,  illegality or unenforceability  shall not affect any
other  provision  or part of a provision of this  Agreement  or the  Transaction
Documents and such provision  shall be reformed and construed as if such invalid
or illegal or unenforceable provision, or part of such provision, had never been
contained herein, so that such provisions would be valid,  legal and enforceable
to the maximum extent possible.

            Section  7.14  Further  Assurances.  From and after the date of this
Agreement, upon the request of any Purchaser or the Company, each of the Company
and the  Purchasers  shall  execute and deliver such  instrument,  documents and
other writings as may be reasonably  necessary or desirable to confirm and carry
out and to  effectuate  fully the intent and  purposes  of this  Agreement,  the
Preferred Shares, the Conversion  Shares, the Warrants,  the Warrant Shares, the
Certificate of Designation, and the Registration Rights Agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       31
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly  executed by their  respective  authorized  officer as of the date first
above written.

                                 DENTALSERV.COM

                                 By:/s/ Lawrence Chimerine
                                    --------------------------------------------
                                    Name:  Lawrence Chimerine
                                    Title: President and Chief Executive Officer

                                 PURCHASER

                                 Sands Brothers Venture Capital  II LLC

                                 By:/s/ Scott Bailey
                                    --------------------------------------------
                                    Name:  Scott Bailey
                                    Title:  Chief Operating Officer

                                 Sands Brothers Venture Capital  III LLC

                                 By:/s/ Scott Bailey
                                    --------------------------------------------
                                    Name:  Scott Bailey
                                    Title:  Chief Operating Officer

                                 Sands Brothers Venture Capital  IV LLC

                                 By:/s/ Scott Bailey
                                    --------------------------------------------
                                    Name:  Scott Bailey
                                    Title:  Chief Operating Officer

                                 Vision Opportunity Master Fund, LTD

                                 By:/s/ Adam Benowitz
                                    --------------------------------------------
                                    Name:  Adam Benowitz
                                    Title:  Director

<PAGE>
                                EXHIBIT A to the
           SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT FOR
                                 DENTALSERV.COM
<TABLE>
<CAPTION>
Names and Addresses                         Number of Preferred Shares          Amount of
of Purchasers                               & Warrants Purchased                Investment
---------------                             --------------------              ----------
<S>                                         <C>                                 <C>

Vision Opportunity Master Fund, Ltd         Preferred Shares: 5,129,407         $10,000,000.00
20 W 55th St., 5th floor                    Series A Warrants: 5,129,407
New York, NY 10019                          Series B Warrants: 5,129,407
                                            Series J Warrants: 5,975,116
                                            Series C Warrants: 5,975,116

Vision Opportunity Master Fund, Ltd         Preferred Shares: 1,025,881         $2,000,000.00
20 W 55th St., 5th floor                    Series A Warrants: 1,025,881        Promissory Note
New York, NY 10019                          Series B Warrants: 1,025,881

Sands Brothers Venture Capital II LLC       Preferred Shares: 76,941            $150,000.00
90 Park Avenue, 31st Floor                  Series A Warrants: 76,941
New York, NY 10016                          Series B Warrants: 76,941

Sands Brothers Venture Capital III LLC      Preferred Shares: 307,765           $600,000.00
90 Park Avenue, 31st Floor                  Series A Warrants: 307,765
New York, NY 10016                          Series B Warrants: 307,765

Sands Brothers Venture Capital IV LLC       Preferred Shares: 128,235           $250,000.00
90 Park Avenue, 31st Floor                  Series A Warrants: 128,235
New York, NY 10016                          Series B Warrants: 128,235
</TABLE>Exhibit 10.1

                        TECHNOLOGY ACQUISITION AGREEMENT

      This Technology Acquisition Agreement (this "Agreement") is made effective
as of  February  19, 2007 (the  "Effective  Date"),  by and among  SGPF,  LLC, a
Kentucky limited  liability  company  ("SGPF"),  Hooman Asbaghi  ("Asbaghi"),  a
resident  of the State of  California,  and  Visual  Connections,  a  California
corporation ("Visual Connections').

                                    RECITALS
      A. Visual  Connections  owns the entire  right,  title and interest in the
following  Patents and Patent  Applications and in the inventions  described and
claimed therein:

            i.    U.S.  Patent  Number  7,198,617  B2,  issued on April 3, 2007,
                  entitled "Passively Guarded, Fillable Injection Syringe".

            ii.   U.S. Patent Application No. 11055415, filed February 10, 2005,
                  entitled "Syringe Guard with Selected Needle Configurations";

            iii.  U.S.  Patent  Application  No.  11140583,  filed May 27, 2005,
                  entitled  "Passively  Guarded,  Pre-filled  Injection Syringe"
                  (ClP);

            iv.   Syringe Guard tor Pre-filled  medicament  vial, US application
                  number 11/211,336 filed on August 25, 2005;

            v.    Hypodermic Needle Tip Protector, Application number 11/422,851
                  filed on June 7, 2006;

            vi.   PCT  Application  No.   US2005/018178,   entitled   "Passively
                  Guarded, Fillable Injection Syringe";

            vii.  PCT Application  No.  US2006/004286,  entitled  "Syringe Guard
                  with Selected Needle Configurations";

            viii. PCT  Application  No.   US2006/004068,   entitled   "Passively
                  Guarded, Prefilled Injection Syringe"; and

            ix.   To be filed: PCT for "Hypodermic Needle tip Protector"

      B. SGPF  desires to obtain  exclusive  ownership of the Patents and Patent
Applications, and certain related technology rights, upon the payment of certain
consideration  set forth in this  Agreement.  Visual  Connections  is willing to
transfer outright ownership of the Patents and Patent Applications,  and certain
related  technology  rights,  to SGPF upon  receipt of certain  payments  and in
consideration of the terms set forth in this Agreement. SGPF desires that Visual
Connections  grant it a  worldwide  exclusive  license in order to profit in the
interim from the  inventions  described in the Patents and Patent  Applications,
and to exploit such related  technology  rights,  all as described more fully in
this Agreement. SGPF agrees to assume all expenses related to patent prosecution
fees and any related fees immediately  upon execution of

<PAGE>

this  Agreement,  except for the  payments  to be made,  actions to be taken and
expenses to be incurred by Visual  Connections  as set forth in this  Agreement.
Visual  Connections  guarantees that all related actions have been executed in a
timely manner in order to maintain all Patent  Applications  and Patents in good
standing.

                                    AGREEMENT

      Incorporating  the above  recitals  herein,  and in  consideration  of the
covenants  and  obligations   contained  herein  and  other  good  and  valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, SGPF
and Visual Connections hereby agree as follows:

1.    Definitions

      For  purposes of this  Agreement  capitalized  terms have the meanings set
forth in this Section or elsewhere in this Agreement.

      1.1 "Adjusted  Gross Sales" as used in this Agreement  means the amount of
revenue  actually  received by SGPF,  including any  Affiliates,  from the sale,
license,  sublicense,  lease,  franchising,  rental or other exploitation of the
Products,  less:  (a) cash,  trade,  quantity  or other  discounts,  credits  or
rebates; (b) sales, use, tariff, import/export duties or other excise or similar
taxes imposed upon particular  sales; (c)  transportation  and related insurance
charges; (d) allowances or credits to customers because of rejections,  returns,
refunds,  billing  errors  or  retroactive  price  reductions;  and (e)  product
liability insurances;  all as calculated in accordance with consistently applied
and  generally  accepted  accounting  principles  as used by SGPF in its  normal
financial reporting.

      1.2  "Affiliate"  as used in this  Agreement  with  respect to a person or
entity means any corporation, company, partnership, joint venture, entity and/or
firm which  controls,  is  controlled  by or is under  common  control with such
person or entity.

      1.3  "Commercialize the Product" means to develop  pre-production  samples
and establish a formal marketing plan with respect to the Product.

      1.4 "Encumbrances" is defined in Section 5.1.

      1.5  "Patents"  means  (a) any  patents  described  in  Recital A above or
patents arising out of the Patent Applications described in Recital A above; (b)
any and all reissues, extensions,  substitutions,  confirmation,  registrations,
re-validations, re-examinations, additions, continuations,  continuation-in-part
or  divisionals of or to such patents,  together with all foreign  corresponding
patents  thereof;  and  (c)  any  other  patents  or such  other  rights  owned,
controlled,  acquired or otherwise  licensable by Visual  Connections or Asbaghi
during the term of this Agreement which would be infringed by SGPF in exercising
its rights  under the license  granted,  or exercise  of the  Technology  Rights
transferred, by this Agreement;

      1.6 "Patent  Applications" means (a) the patent applications  described in
Recital A above and (b) any other U.S. or foreign patent  applications  that may
be filed with respect to the

                                       2
<PAGE>

Technology  or the Product,  and any  continuations,  continuations-in-part  and
divisions of these applications.

      1.7 "Permits" is defined in Section 5.1(b).

      1.8 "Product" means the Safety Syringe  System,  with and without a Distal
Protective Needle, in a Fillable and Pre-filled  Configuration,  as described on
Exhibit  A to  this  Agreement  and  covered  by  the  Patents  and  the  Patent
Applications.

      1.9 "Royalty Payment" is defined in Section 2.3.

      1.10 "Technology" means (a) the technology described on the Description of
the Safety Syringe Device and the Product,  in multiple  configurations as noted
in this  Agreement,  and as attached to this Agreement as Exhibit A, and (b) all
knowledge, information, know-how, discoveries,  procedures, devices, techniques,
programs,   inventions,   creations,  methods,  protocols,  formulas,  software,
designs,  drawings,  works  of  authorship  and  other  valuable  technical  and
proprietary  information  related to such technology,  the Safety Syringe Device
and the Product that have been  developed by or on behalf of Visual  Connections
as of the  date of this  Agreement.  Such  know-how  described  in the  previous
sentence  includes,  but is not  limited  to,  proof of concept  and all efforts
necessary to ensure  manufacturability of all of the above mentioned.  This does
NOT mean additional refinements may not be necessary.

      1.11 "Technology Documents" is defined in Section 5.2.

      1.12  "Technology  Rights" means all present and future  right,  title and
interest in and to any and all intellectual property rights throughout the world
in and relating to the Technology,  including,  without limitation,  any and all
patents  (including  the Patents),  patent  applications  (including  the Patent
Applications),  copyrights,  copyright  applications,  trademarks (including the
Trademarks), trade secret rights, rights to know-how, inventions and algorithms,
and any and all similar or equivalent rights throughout the world.

      1.13 "Technology Transfer Time" is defined in Section 5.l.

      1.14  "Trademarks"  means  all  trademarks,   trademark  applications  and
tradenames related to the Product.

      1.15  "Verified  the  Patents"  means  that SGPF has  reviewed  the Patent
Applications   and  the  Patents  for  issues   affecting   SGPF's   ability  to
Commercialize  the Product,  including ability to market and profitably sell the
Product  and SGPF has  reviewed  the Patent  Applications  and the  Patents  for
infringement  issues,  and has determined,  in its reasonable  discretion,  that
there  are  no  issues  which  would   materially   hinder  SGPF's   ability  to
Commercialize  the Product,  profitably  market and sell the Product and utilize
the Technology Rights.

2.    Payments and Royalties for License and Technology Transfer

      2.1 Payment for Transfer of Technology  Rights.  In  consideration  of the
transfer to SGPF by Visual  Connections  of the  Technology  Rights  pursuant to
Section 5 of this Agreement,  SGPF will pay to Visual  Connections the following
contingent technology transfer payments if

                                       3
<PAGE>

such payments are triggered  pursuant to the  requirements  in this Section (the
payments set forth below, to the extent they are triggered, shall be referred to
herein collectively as the "Technology  Transfer Payment").  If only the Initial
Technology  Transfer Payment is triggered,  it shall constitute the sole, and be
sufficient,  consideration for the transfer of the Technology Rights. Payment of
the Initial  Technology  Transfer  Payment does not eliminate any obligation for
SGPF to pay the remainder of the  Technology  Transfer  Payment and provided for
below.

            (a)  Up to Three  Million  Dollars  ($3,000,000.00)  will be paid to
      Visual Connections as follows:

                  (i)  Two Hundred Fifty Thousand Dollars  ($250,000.00) will be
      paid to Visual  Connections  by SGPF ten (10) days after the  execution of
      this Agreement (the "Initial Technology Transfer Payment");

                  (ii) Two Hundred Fifty Thousand Dollars  ($250,000.00) will be
      paid to Visual  Connections by SGPF one hundred eighty (180) days from the
      previous  payment  if, and only if,  SGPF has  successfully  verified  the
      Patents within 150 days of the date of this Agreement;

                  (ii)  Five Hundred Thousand Dollars ($500,000.00) Dollars will
      be paid to Visual  Connections  one  hundred  eighty  (180)  days from the
      previous  payment  if, and only if,  SGPF has  successfully  verified  the
      Patents within 150 days of the date of this Agreement; and

                  (iii)  Thereafter,  SGPF will pay to Visual  Connections eight
      (8) consecutive  quarterly  payments of Two Hundred Fifty Thousand Dollars
      ($250,000.00),  each commencing ninety (90) days from the previous payment
      if, and only if, SGPF has  successfully  verified  the Patents  within 150
      days of the date of this Agreement.

      2.2  Other  Payments.  In  addition  to the  Technology  Transfer  Payment
required  from SGPF to acquire the  Technology  Rights,  SGPF agrees to make the
royalty payments as provided in Section 2.3 below to Visual Connections pursuant
to the terms of this  Agreement.  So long as SGPF pays the  Technology  Transfer
Payment  to  Visual  Connections  pursuant  to  Section  2.1 of this  Agreement,
however, Visual Connections' remedy for any claimed breach by SGPF in connection
with the payments set forth in this Section 2.2 and Section 2.3 does not include
a restoration  of ownership of the Technology  Rights,  Product or Technology to
Visual Connections.

      2.3  Royalty  Payments.  SGPF  agrees  to  pay  the  following  to  Visual
Connections:

            (a)  SGPF  agrees to pay to Visual  Connections  or its  designee  a
      royalty  payment based upon a percentage  of Adjusted  Gross Sales for any
      Product sold by SGPF or any of its Affiliates (a "`Royalty Payment").  For
      each  calendar  year in which  Royalty  Payments are  applicable  per this
      section,  the Royalty  Payment  shall be equal to five  percent  (5.0%) of
      Adjusted Gross Sales for any Product sold by SGPF or any of its Affiliates
      until the total of all Royalty  Payments for such calendar year equals Two
      Hundred and Fifty Thousand  Dollars  ($250,000.00).  At such time, and for
      the remainder of each calendar year, the Royalty  Payment shall be reduced
      to four percent  (4%) of

                                       4
<PAGE>

      Adjusted Gross Sales of any Product sold by SGPF or any of its Affiliates.
      SGPF  covenants and agrees that all Royalty  Payments under this Agreement
      shall  survive  any sale,  license,  sublicense  or other  transfer of the
      Patents or Patent  Applications to an Affiliate or a third party, but that
      SGPF will be  relieved  of the duty to pay the  Royalty  Payments  if such
      transferee;  licensee or  sublicensee  agrees to directly pay such Royalty
      Payments to Visual Connections.  The obligation to pay the Royalty Payment
      shall  commence  on the later of the date that is  thirty-six  (36) months
      from the signing of this  Agreement,  or six (6) months  after the sale of
      the first Product,  but such  obligation  shall only be due and payable in
      accord  with  Section  6.1  hereof.  The  obligation  to pay the five (5%)
      percent  royalty shall not be  applicable in the initial  calendar year in
      which the Royalty Payments are triggered.

            (b)  Subject  to  Section  12.2  below,  and  continuing  until  the
      termination of the first Patent:

            (i) SGPF will use its  commercially  reasonable  efforts to commence
      production  and sales of the  Product(s)  ("Production")  within two years
      from the date of this Agreement.

            (ii)  SGPF shall  have the right to  terminate  Visual  Connections'
      royalty rights under this Section 2.3, if Visual Connections so agrees, by
      tendering  to  Visual  Connections,  at any time,  an amount  equal to the
      anticipated  Royalty Payment for the life of the Patents  discounted by an
      appropriate  discount rate, which such rate takes into  consideration  the
      time value of money and the risk  related to the  likelihood  of receiving
      the  anticipated  Adjusted  Gross  Sales  giving  rise to the  anticipated
      Royalty Payment (the "Royalty Payoff  Amount").  If the parties hereto can
      not agree on the Royalty Payoff Amount,  SGPF and Visual Connections shall
      each  appoint a certified  public  accounting  firm and the two  certified
      public  accounting  firms so chosen shall appoint a third certified public
      accounting firm  (collectively,  the  "Appraisers").  The Appraisers shall
      determine the Royalty  Payoff Amount and such amount shall  irrefutably be
      the Royalty Payoff Amount.  If Visual  Connections  does not agree to such
      Royalty Payoff Amount and its  termination of the Royalty  Payments,  SGPF
      can offer a 10% premium (the  "Premium") in addition to the Royalty Payoff
      Amount and Visual Connections shall be required to accept such Premium and
      Royalty  Payoff  Amount  and  such  payment  shall  terminate  any  future
      obligation to pay any Royalty Payment.

            (iii) SGPF shall not accrue any obligation in the event that SGPF is
      unable  to  commercialize  the  Product  due to  manufacturability  issues
      (including  limitations caused by direct  manufacturing  cost), failure to
      receive  patent   acceptances,   technological   obsolescence   or  patent
      infringement opinions.

            (iv) SGPF will initiate  pre-production efforts to Commercialize the
      Product in a timely manner,  and will develop a schedule for these efforts
      as soon as  practical.  SGPF will make  reasonable  efforts  to engage Don
      Millerd of MUE  Corporation  ("MUE") as the technical  project manager for
      the development of the Product. SGPF and Millerd have reviewed the Product
      and the  Technology  in an attempt to  determine  the efforts  required to
      complete all  engineering  efforts  necessary to develop  proof of concept
      tooling.  All parties,  including Visual  Connections,  SGPF and MUE, have
      agreed  that the entire  effort to produce  engineering  drawings to build
      tools and tooling for the  manufacture  of the

                                       5
<PAGE>

      Product  (the  "Engineering  Drawings")  will not exceed One  Hundred  and
      Twenty Five Thousand  Dollars  ($125,000.00)  (the  "Engineering  Drawings
      Cost").  SGPF  will be  responsible  for the  payment  of the  Engineering
      Drawings  Cost,  but such cost  will be  deducted  from the first  Royalty
      Payments to become due hereunder  until the  Engineering  Drawings Cost is
      fully  recouped  by  elimination  of the first One Hundred and Twenty Five
      Thousand Dollars ($125,000.00) of Royalty Payments that would otherwise be
      due and owing to Visual  Connections,  in the event that modifications are
      required  after the  construction  of the initial  tools,  SGPF and Visual
      Connections   will  mutually   determine  the   responsibility   for  such
      modifications,  and determine  what portion of the payments will be deemed
      product enhancements as opposed to costs for Engineering Drawings. If SGPF
      determines  that it wishes to request  modifications  to the Product  that
      were not originally  contemplated in the design,  and these  modifications
      are not required for functionality or patent office action response,  then
      SGPF shall be  responsible  for such payments  without  deduction of these
      amounts  from  Royalty  Payments.  If charges  as defined in this  section
      exceed  the  Engineering   Drawings  Cost,  Visual  Connections  shall  be
      responsible  for providing MUE with a satisfactory  payment,  or develop a
      mutually acceptable plan for payment, with SGPF, whichever SGPF chooses.

3.    Grant of License to SGPF

      3.l  Grant.  Visual  Connections  and  Asbaghi  hereby  grant  to  SGPF an
exclusive,  worldwide, right and license, with the right to grant sublicenses as
hereinafter  set forth, to use the Technology  Rights and the Technology,  which
such license permits SGPF to construct,  hire others to construct, use, promote,
market, offer for sale and sell the Product and the Technology.

      3.2  Sublicenses.  SGPF may grant  sublicenses  of the  Technology  Rights
without the approval of Visual  Connections.  If SGPF grants any  sublicenses of
the  Technology  Rights,  it shall  promptly  notify Visual  Connections of such
sublicense  and  provide  Visual  Connections  with a copy  of  such  sublicense
agreement.  All payment provisions as described in this agreement shall apply to
any such sub-license unless otherwise agreed by both SGPF and Visual Connections
except that in no instance shall Visual  Connections be entitled to greater than
100% of the  Technology  Transfer  Payment  or  Royalty  Payment  as  calculated
hereunder;  provided,  however, that the Royalty Payment shall be based upon the
Adjusted Gross sales for SGPF and any sublicensee.

4.    SGPF Right of First Refusal

      4.1 Right of first Refusal.  Visual  Connections  and Asbaghi hereby grant
SGPF the right of first refusal to enter into an acquisition, licensing or other
agreement  to  commercialize   any  additional  Visual   Connections'   products
including,  without  limitation,   rights  related  to  research,   development,
manufacturing,  marketing and sales. Prior to entering into a  commercialization
agreement with any third party with respect to such additional products,  Visual
Connections  will first  negotiate in good faith with SGPF for such  rights.  If
SGPF  and  Visual  Connections  are  unable  to enter  into a  commercialization
agreement  within  ninety  (90)  days of  beginning  negotiations,  then  Visual
Connections  will be free to enter into  negotiations  with another  third party
concerning such an agreement;  provided,  however,  that Visual Connections will
not enter into a commercialization agreement with any other third party on terms
in the  aggregate  less  attractive  to Visual  Connections  than the terms last
offered by SGPF

                                       6
<PAGE>

without  first  giving SGPF the  opportunity  to enter into a  commercialization
agreement on such terms.

5.    Transfer of Technology Rights and Certain Payments and Actions

      5.1 Technology  Rights.  Effective upon the payment by SGPF of the Initial
Technology Transfer Payment to Visual Connections  pursuant to Section 2.1 above
(the  "Technology  Transfer Time"),  Visual  Connections  hereby grants,  sells,
assigns,  transfers,  conveys and delivers to SGPF,  its successors and assigns,
forever,  free and  clear  of all  title  detects,  objections,  liens,  claims,
pledges,  rights  of  first  refusal,   options,  charges,  security  interests,
mortgages or other  encumbrances  of any nature  whatsoever  (collectively,  the
"Encumbrances"):

            (a) (i) all right, title and interest in and to the Technology,  the
      Product and the  Technology  Rights;  (ii) all rights of priority  and all
      rights and claims for past  infringement of the Patents or the Trademarks;
      and (iii) the fun and unrestricted right to use, develop, enhance, modify,
      improve and assign,  license or  otherwise  transfer the  Technology,  the
      Patents,  the Patent  Applications  and the Trademarks,  and to make, use,
      sell and  lease  the  Product  and any other  products  incorporating  the
      Technology;

            (b) to the extent transferable, all licenses, permits, applications,
      registrations,  authorizations,  orders,  or approvals of  governmental or
      quasi-governmental  agencies  and  authorities  (whether  federal,  state,
      local, municipal or foreign), including, without limitation, any clearance
      certificates  or  marketing   approvals   issued  by  the  Food  and  Drug
      Administration  (the  "FDA"),  relating  to  the  manufacture,  marketing,
      distribution or use of the Product (collectively, "Permits"); and

            (c)  originals  or copies of all books,  records,  files and papers,
      whether  in hard copy or  computer  format,  used in  connection  with the
      Technology  including,  without  limitation,   manuals  and  data,  notes,
      drawings,   sales  and   advertising   materials,   sales   and   purchase
      correspondence,   design  history  files,  lists  of  present  and  former
      suppliers  and  any and all  documentation  or  materials  that  have  any
      relevance  or bearing on the  Technology,  the Product and the  Technology
      Rights.

Visual Connections covenants that it shall not permit any Encumbrances to attach
to the  Patents,  Patent  Applications,  Technology,  Technology  Rights  or the
Product.

5.2   Certain Payments and Actions.

            (a)   Visual   Connections   recognizes  that   additional   Product
      documentation  and other similar  supporting  materials may be required by
      SGPF to properly commercialize the Product as described in this Agreement.
      Visual  Connections  shall  comply  with  any  requests  by SGPF  for such
      materials as are  beneficial to the success of the project,  and, as such,
      will in good  faith  agree  to take  all such  necessary  action,  without
      hesitation,  to create  the  additional  Product  documentation  and other
      similar supporting  materials  requested by SGPF from time to time. Visual
      Connections  further agrees,  notwithstanding  any other provision of this
      Agreement,  to pay all initial patent  application  filing fees related to
      such supporting  documentation to help protect any novel

                                       7
<PAGE>

      features  that may need  protection  as  determined by counsel for SGPF or
      Visual  Connections.  Such patent  applications will automatically  become
      part of the Patents and the Patent Applications described in the recitals.
      SGPF agrees and acknowledges  that this provision  refers  specifically to
      documentation  that will be  required to support  FDA  clearance  filings,
      current  parent  application  filings  and similar  regulatory  or support
      requirements, including, but not limited to, the following:

                  (i) Completion of all US Patent Applications thru issuance;

                  (ii)  Documentation  deficiencies  regarding all future 510(k)
            FDA filings by SGPF; and

                  (iii)  Additional  engineering  costs  associated with initial
            manufacturability  to be  completed  by Visual  Connections  and MUE
            Corporation; provided, however, that payment of these expenses shall
            be governed by Section 2.3(b)(iv).

            (b) Visual  Connections  agrees to pay 50% of all costs arising from
      any  infringement  action filed in connection  with the Product,  whenever
      such action is filed.

            (c)  SGPF  agrees that Visual  Connections'  obligations  under this
      Section 5.2(a)(i) and (a)(ii) are exclusive of Patent prosecution costs in
      their general context,  and this section only requires Visual  Connections
      to provide  materials  related to pending  application  documentation  and
      supporting   material   requirements,   except  as   required  by  Section
      5.2(a)(ii),   (a)(iii)  and  (b).   Further,   any  infringement   defense
      requirements  pertain to unaltered product designs. In the event that SGPF
      requires material Product  modifications,  it will accept the infringement
      burden related to such modifications.

            (d) Visual Connections will take no action,  directly or indirectly,
      to seek: or cause or  facilitate  another to seek or cause (i) a receiver,
      liquidator or trustee to be appointed  with respect to Visual  Connections
      or of  any  of the  properties  or to  take  possession  of  any of  their
      respective  properties,  (ii) Visual  Connections to generally fail to pay
      its debts as they become due or admit in writing its  inability to pay its
      debts as they mature,  (iii) Visual Connections to be adjudicated bankrupt
      or  insolvent  or to have any of its material  properties  sequestered  by
      court  order,  or  (iv)  a  petition  to be  filed  by or  against  Visual
      Connections under any bankruptcy, reorganization. arrangement, insolvency,
      readjustment of debt,  dissolution or liquidation law of any jurisdiction,
      whether now or subsequently in effect.

      5.3  Instruments  of  Conveyance.  Upon the  execution of this  Agreement,
Visual  Connections  will  execute  and  deliver  to  SGPF,  to hold  until  the
Technology  Transfer  Time,  all such  documents or  instruments  of assignment,
transfer, notice or conveyance as SGPF reasonably deems necessary or appropriate
to vest in, confirm title to and prove SGPF's rights to the  Technology  Rights.
Technology  and  Product in  accordance  with the terms of this  Agreement  (the
"Technology  Documents").  SGPF will hold these  documents  until the Technology
Transfer Time. Visual Connections shall be entitled to retain a copy of all such
Technology Documents and hereby is granted a security interest in the Technology
Rights to secure the payment of the Technology Transfer Payment.  SGPF will take
all acts  necessary,  but only as requested by

                                       8
<PAGE>

Visual Connections from time to time, to perfect such security interest in favor
of Visual  Connections,  and such security interest shall terminate upon payment
of the  Technology  Transfer  Payment (to the extent the payments  composing the
Technology  Transfer  Payment are  triggered)  or  termination  or waiver of the
obligation by SGPF to make such Technology  Transfer Payment.  In the event that
SGPF  fails to make any  Technology  Transfer  Payment  due and  owing to Visual
Connections,  and any cure period has lapsed,  SGPF will transfer the Technology
Rights back to Visual Connections at its sole cost and expense.

      5.4 Verification of the Patents. SGPF has one hundred and fifty (150) days
within  which to verify the  Patents.  If SGPF is not able to verify the Patents
within  such  time,  SGPF shall  provide  notice to Visual  Connections  of such
failure and the issues or facts  giving rise to such  failure.  Upon  receipt of
such  notice,  Visual  Connections  shall  have the right to offer a cure to the
issues or facts giving rise to the failure to verify the Patents.  SGPF, in it's
reasonably  discretion,  taking  into  account  profitability,  has the right to
accept or reject such cure. If such cure is accepted, the payments composing the
Technology Transfer Payment shall become due and payable, with the first payment
due one hundred  eighty (180) days after the date any such accepted cure becomes
effective.

      5.5 Further  Assurances.  Each party hereto will, before, at and after the
Effective Date,  execute and deliver such other  instruments and take such other
actions  as the  other  party or  parties,  as the case may be,  may  reasonably
require in order to carry out the intent of this Agreement. Without limiting the
generality of the foregoing,  at any time after the Technology Transfer Time, at
the request of SGPF and without further  consideration,  Visual Connections will
execute and deliver  such further  instruments  of sale,  transfer,  conveyance,
assignment and  confirmation  and take such action as SGPF may  reasonably  deem
necessary or desirable in order to more effectively transfer,  convey and assign
to SGPF,  and to confirm  SGPF's  title to, all of the  Technology  Rights,  the
Technology  and the  Product and to assist  SGPF in  exercising  all rights with
respect thereto.

6.    Payments; Books and Records

      6.1  Payments.  All  royalties  payable to Visual  Connections,  or Visual
Connections'  designee,  under this Agreement will be paid twice yearly,  on the
last business day of January with respect to Adjusted  Gross Sales for the first
six months of the prior  calendar year and on the last business day of July with
respect to Adjusted  Gross  Sales for the last six months of the prior  calendar
year,  without  interest.  Each royalty  payment win be accompanied by a written
statement  showing the aggregate  Adjusted  Gross Sales received by SGPF for the
period to which such  royalty  payment  relates  and the  amount of the  royalty
payable to Visual  Connections  in  respect  thereof,  together  with such other
information as Visual Connections may reasonably request.  SGPF agrees to submit
such  statements  beginning  with the first  Royalty  Payment  made  pursuant to
Section 2.3.

      6.2 Books and Records.  SGPF agrees to keep complete and accurate books of
account and  records  covering  all  transactions  relating  to this  Agreement,
including  technical records,  which will enable Visual Connections to determine
which products of SGPF are Products under this Agreement. Visual Connections and
Visual  Connections' duly authorized  representatives and auditors will have the
right,  up to two (2) times in each calendar  year,  on reasonable  notice of at
least two weeks, to audit SGPF's books of account and records that relate to the
subject

                                       9
<PAGE>

matter and terms of this  Agreement.  All such books of account and records must
be kept  available  for at least two (2) years  after  the  termination  of this
Agreement Visual Connections will not have any right to audit any other books of
account  or  records  of SGPF.  Upon  three (3)  days'  written  notice,  Visual
Connections  shall  conduct  any  inspections  of the records of SGPF at its own
expense;  provided,  however,  that if any  audit  reveals a  material  negative
discrepancy  in the  cumulative  Royalty  Payments made through the date of such
audit in an amount of more than five (5%),  SGPF shall  immediately pay the cost
of such audit

7.    Representations and Warranties of Visual Connections

      Visual  Connections  and Asbaghi  represent  and warrant to SGPF as of the
date hereof, which representations and warranties are material, are being relied
upon by SGPF (not withstanding any independent  investigation)  and will survive
the date hereof, as follows:

      7.1  Organization,   Power.  Visual  Connections  is  a  corporation  duly
organized,  validly existing and in good standing under the laws of the state of
California and has all requisite  corporate  power and authority to carry on its
business as it is now being conducted,  to own, lease and operate its properties
and  assets,  to enter  into this  Agreement  and to carry out the  transactions
contemplated hereby.

      7.2 Authorization, Execution. The execution and delivery of this Agreement
and  the  consummation  of the  transactions  contemplated  hereby  will be duly
authorized by the Board of Directors  and  shareholders  of Visual  Connections.
This Agreement has been duly executed and delivered by Visual  Connections,  and
constitutes a valid and legally binding  obligation  enforceable  against Visual
Connections in accordance with its terms.

      7.3  Conflicts.  Neither the execution and delivery of this  Agreement nor
the performance of the provisions hereof or the transactions contemplated hereby
by Visual Connections (a) violates or conflict with any organizational,  charter
or governing documents; (b) violates or conflicts with any applicable law, rule,
regulation, writ, judgment,  injunction,  decree, determination,  award or other
order of any  court,  government  or  governmental  agency  or  instrumentality,
domestic  or  foreign,  or (c)  results  in any breach of any of the terms of or
constitutes  a default  under or results in the  creation or  imposition  of any
mortgage,  deed of trust,  pledge,  lien,  security  interest or other charge or
Encumbrance  of any nature  pursuant to the terms of any contract,  agreement or
instrument  to  which  Visual  Connections  is a  party  or by  which  it or its
properties or any of the Technology, Technology Rights or Product is bound.

      7.4 Technology Rights.

            (a) Visual  Connections is the exclusive record and beneficial owner
      of the Technology Rights (including  without  limitation the Product,  the
      Patents,  the Patent  Applications and the Trademarks),  free and clear of
      all Encumbrances. Visual Connections has full rights and powers to, and at
      the  Technology  Transfer Time will deliver to SGPF,  good and  marketable
      title to all of the Technology Rights, free and clear of any Encumbrance.

            (b)  The use of Patents,  Trademarks  and  Technology  necessary  or
      required  for  the  conduct  of the  business  of  Visual  Connections  as
      presently conducted and as

                                       10
<PAGE>

      proposed to be conducted by SGPF does not and will not infringe or violate
      any trade secrets, plans and specifications,  patents,  copyrights,  trade
      names,  registered  and common  law  trademarks,  trademark  applications,
      service  marks,  service mark  applications,  computer  programs and other
      computer software, inventions, know-how, technology, proprietary processes
      and formulae or other intellectual  property rights of any other person or
      entity  (the  "Third  Party   Intellectual   Property   Rights").   Visual
      Connections is not using any confidential  information or trade secrets of
      others.

            (c)  The  Patents and Patent  Applications  are in  compliance  with
      formal legal  requirements  (including the payment of filing,  examination
      and  maintenance  fees and  proofs  of  working  or use),  are  valid  and
      enforceable  and are not  subject to any fees or taxes or actions  falling
      due within ninety (90) days after the date of this Agreement.  The Patents
      and, as applicable, the Patent Applications, are valid and enforceable and
      have not been,  and are not now,  involved in any  interference,  reissue,
      reexamination,  opposition,  declaratory  judgment  or other  invalidating
      proceeding,  nor is any such action threatened with respect to the Patents
      or the Patent  Applications.  No applications  for potentially  infringing
      patents have been filed and no  potentially  infringing  patents have been
      issued.  No  Trademarks  have  been  or are  involved  in any  opposition,
      invalidation  or  cancellation  proceeding,  and there is no basis for the
      commencement  of  any  such  proceeding.  The  Trademarks  are  valid  and
      enforceable  and no person holds any infringing or potentially  infringing
      trademark and no application for any infringing or potentially  infringing
      trademark has been made.

            (d)  A  copy  of  all  documentation   related  to  the  Technology,
      Technology  Rights  and the  Product  has been  furnished  to  SGPF.  Such
      documentation is current, accurate,  complete and in sufficient detail and
      content to explain  all aspects of the  Technology  and to allow it's full
      and  proper  use  without  reliance  on  the  memory  of  others.   Visual
      Connections  has  not  suffered  or  allowed  any of the  Patents,  Patent
      Applications,  Trademarks  or other  Technology  Rights to enter  into the
      public domain, nor has the Technology been used,  divulged or appropriated
      for the benefit of any person or entity other than Visual  Connections  or
      to the detriment of Visual  Connections.  Visual Connections has taken all
      measures and precautions necessary to protect the secrecy, confidentiality
      and value of the Technology.

            (e)  Visual  Connections  is not  obligated  or under any  liability
      whatsoever to make any payments by way of royalties,  fees or otherwise to
      any person  claiming to be an owner of, licensor of, or other claimant to,
      any of the Patents, Patent Applications,  Trademarks, Technology Rights or
      Technology or any Third Party Intellectual Property Rights.

            (f) All employees, contractors and consultants of Visual Connections
      involved in the technical or scientific  aspects of the business of Visual
      Connections,  both past and present, have executed written agreements with
      Visual  Connections  which assign to Visual  Connections all rights to any
      inventions,  improvements,  discoveries  or  information  which  relate to
      Visual  Connections'  business.  No employee,  contractor or consultant of
      Visual  Connections  has entered  into any  agreement  which  restricts or
      limits  in any way the  scope  or type  of work in  which  such  employee,
      contractor  or  consultant  may be  engaged  or  requires  such  employee,
      contractor or consultant to transfer, assign or

                                       11
<PAGE>

      disclose   information   concerning  such   employee's,   contractor's  or
      consultant's work to anyone other than Visual Connections.

      7.5 Permits.  Visual  Connections (a) has provided SGPF with all consents,
approvals,  governmental filings, authorizations,  and permits in its possession
for (i) the consummation of the transactions  contemplated by this Agreement and
(ii)  the  continued  manufacture,  distribution  and  use  of the  Product  and
Technology,   including,  without  limitation,  any  clearance  certificates  or
marketing  approvals issued by the FDA, relating to the manufacture,  marketing,
distribution  or use of the Product;  and (b) has  maintained  in full force and
effect and renewed, when required, all Permits.

      7.6 Instruments of Conveyance.  The Technology Documents are sufficient to
transfer all right, title and interest in the Patents,  the Patent Applications,
the Technology, the Technology Rights and the Product to SGPF.

      7.7 Statements.  Neither this Agreement nor any exhibit, certificate, list
or other  document  furnished  or to be  furnished  by or on  behalf  of  Visual
Connections  pursuant  to this  Agreement  contains  or will  contain any untrue
statement  of  material  fact or omits or will  omit to  state a  material  fact
necessary to make the statements  contained herein and therein,  in light of the
circumstances  under which they are made, not  misleading.  There is no material
fact as of the date hereof  which has not been  disclosed  in writing to SGPF to
which Visual Connections has knowledge related to the Product, the Technology or
the  Technology  Rights  which  could have a material  adverse  effect on SGPF's
ability to fully use the Product, the Technology or the Technology Rights.

      7.8 Litigation. There is no legal,  administrative,  arbitration, or other
proceeding, suit, claim or action of any nature or investigation review or audit
of any kind,  judgment,  decree,  decision,  injunction,  writ or order pending,
noticed,  scheduled or threatened or contemplated by or against or involving the
Product,  the Technology or the Technology Rights,  whether at law or in equity,
before or by any person or entity or Authority, or which questions or challenges
the validity of this Agreement or any action taken or to be taken by the parties
hereto  pursuant  to this  Agreement  or in  connection  with  the  transactions
contemplated  herein.  For  purposes of this  Agreement,  "Authority"  means any
foreign,   federal,   state   or  local   government,   government   agency   or
instrumentality,  administrative,  regulatory  or  judicial  court,  department,
commission, agency, bureau, instrumentality or other authority.

      7.9  Compliance  with  Law;  Permits;  Consents.  Visual  Connections  has
complied  with  all laws  applicable  to the  Product,  the  Technology  and the
Technology Rights. No Consent,  approval order, notice to or other authorization
of any Authority, or of any other third parties, are required in connection with
the execution,  delivery or performance of this Agreement by Visual  Connections
or the  consummation  by Visual  Connections  of the  transactions  contemplated
herein or therein,  except for the  Instruments of  Conveyance.  For purposes of
this Agreement, "Consent" means any consent, approval, order or authorization of
or  from,  or  registration,   notification,  declaration  or  filing  with  any
individual or Authority, including without limitation any Authority.

      7.10  Books  and  Records.  The books and  records  of Visual  Connections
relating to the Technology are complete and correct in all material respects and
have been maintained in

                                       12
<PAGE>

accordance with Visual Connections' past business practices and copies have been
provided to SGPF.

      7.11 Product Liability.  Visual Connections has no liability (and there is
no basis for any  present  action,  suit,  proceeding,  hearing,  investigation,
charge,  complaint,  claim or  demand  against  any of them  giving  rise to any
liability)  arising out of any injury to  individuals or property as a result of
the  ownership,  possession,  or use  of  the  Product,  the  Technology  or the
Technology Rights.

      7.12  Taxes.  Visual  Connections  has  filed or  caused  to be filed  all
federal,  state,  municipal  and other tax  returns,  reports  and  declarations
required  to be filed by it on or before the date  hereof so as to  prevent  any
Encumbrance  of any nature on the Product,  the  Technology  and the  Technology
Rights, and, except as otherwise provided herein, has paid or will pay all taxes
which have been or will become due with  respect to the periods  covered by said
returns and any period prior to the date hereof,  or pursuant to any  assessment
received by it in connection  therewith.  All assessments and charges (including
penalties and interest, if any) have been paid by Visual Connections,  including
any  necessary  adjustments  with  state  and  local  tax  authorities,  and  no
deficiency  in  payment of any taxes for any  period  has been  asserted  by any
taxing authority which remains unsettled at the date hereof.

      7.13 All Necessary  Assignments.  The  assignments  by Visual  Connections
pursuant to this Agreement  will  constitute an assignment of all the Technology
Rights and all rights, whether defined as Technology Rights or otherwise, to the
Product and the Technology.

      7.14 Additional  Representations  and Warranties.  Visual  Connections and
Asbaghi represent and warrant, and covenant, as applicable, to SGPF that:

            (a) Visual  Connections and Asbaghi have entered into this Agreement
      in good  faith  and for  bona  fide  business  purposes,  and the sale and
      purchase of the Technology Rights is an arm's length  transaction which is
      fair,  reasonable and in the best interest of both Visual  Connections and
      SGPF.

            (b)  The  consideration  received  by  Visual  Connections  for  the
      Technology Rights pursuant to this Agreement, regardless of which payments
      are actually triggered going forward, is as of the date hereof sufficient,
      substantial, valuable, fair and adequate consideration for the purchase of
      the Technology  Rights, and Visual Connections has received the reasonably
      equivalent  value for the  Technology  Rights being sold to SGPF such that
      there is reasonable  equivalence between the consideration and the current
      fair market value of the Technology Rights.

            (c)  In  connection   with  the   examination   by  SGPF  of  Visual
      Connections' books and records relating to the Technology  Rights,  Visual
      Connections  has  provided  SGPF  with  all  necessary  documentation  and
      information  to  perform  such  audits,  that  all  such  information  and
      documentation  furnished  to SGPF  was true and  correct  and that  Visual
      Connections  has provided  SGPF with all the necessary  documentation  and
      information in order for SGPF to fairly assess the value of the Technology
      Rights  and to  determine  that the  consideration  is fair  and  adequate
      consideration for the Technology Rights.

                                       13
<PAGE>

            (d) Visual Connections is not entering into this Agreement or any of
      the  agreements  related  to this  transaction  with the intent to hinder,
      delay, defeat or defraud any of Visual Connections' existing creditors, or
      any other  person,  any rights such  creditors may have against SGPF or to
      place the Technology Rights beyond the reach of the creditors or to hinder
      creditors  in  the  collection  of  their  claims  against  SGPF.   Visual
      Connections  agrees that the transfer of the Technology  Rights to SGPF is
      not being  made  with the  intent to evade or  escape  any  liability  for
      existing  debts,  or to avoid  any duty or debt due by, or  incumbent  on,
      Visual Connections.

8.    Representations and Warranties of SGPF

      SGPF represents and warrants to Visual  Connections as of the date hereof,
which  representations  and  warranties  are material,  are being relied upon by
Visual  Connections (not  withstanding any independent  investigation)  and will
survive the date hereof, as follows:

      8.1 .  Organization,  Power.  SGPF is a  limited  liability  company  duly
organized,  validly existing and in good standing under the laws of the slate of
Kentucky and has all  requisite  power and authority to carry on its business as
it is now being conducted,  to own, lease and operate its properties and assets,
to enter  into this  Agreement  and to carry out the  transactions  contemplated
hereby.

      8.2 Authorization, Execution. The execution and delivery of this Agreement
and  the  consummation  of the  transactions  contemplated  hereby  will be duly
authorized  by the Board of  Directors  of SGPF.  Subject to the receipt of such
authorization,  this Agreement has been duly executed and delivered by SGPF, and
constitutes a valid and legally binding obligation  enforceable  against them in
accordance with its terms.

      8.3  Conflicts.  Neither the execution and delivery of this  Agreement nor
the performance of the provisions hereof or the transactions contemplated hereby
by SGPF violate or conflict  with (a) any  organizational,  charter or governing
documents;  or  (b)  any  applicable  law,  role,  regulation,  writ,  judgment,
injunction, decree, determination, award or other order of any court, government
or governmental agency or instrumentality, domestic or foreign.

      8.4 Statements.  Neither this Agreement nor any exhibit, certificate, list
or other document  furnished or to be furnished by or on behalf of SGPF pursuant
to this Agreement contains or will contain any untrue statement of material fact
or omits or will omit to state a material fact  necessary to make the statements
contained herein and therein, in light of the circumstances under which they are
made, not misleading.

      8.5 Litigation. There is no legal,  administrative,  arbitration, or other
proceeding,  suit,  claim or action of any  nature or  investigation,  review or
audit  of any  kind,  judgment,  decree,  decision,  injunction,  writ or  order
pending, noticed, scheduled or threatened or contemplated,  whether at law or in
equity,  before or by any  person or entity or  Authority,  which  questions  or
challenges  the validity of this Agreement or any action taken or to be taken by
the  parties  hereto  pursuant  to this  Agreement  or in  connection  with  the
transactions contemplated herein.

                                       14
<PAGE>

      8.6 Compliance with Law; Permits;  Consents.  No Consent,  approval order,
notice  to or  other  authorization  of any  Authority,  or of any  other  third
parties, are required in connection with the execution,  delivery or performance
of  this  Agreement  by  SGPF or the  consummation  by SGPF of the  transactions
contemplated herein or therein.

9.    Term and Termination

      9.1 Generally.  The term of this Agreement will commence on the date first
set forth above.  Except for the royalty payment obligations of SGPF pursuant to
Sections  2.3,  which shall remain in effect for the period set forth in Section
2.3, this Agreement shall expire upon the  termination of the latest  expiration
date of the Patents.  Notwithstanding  the  foregoing,  this  Agreement  and the
obligations  of the parties  hereunder may be terminated in accordance  with the
following provisions:

            (a) Prior to the payment by SGPF of the Technology Transfer Payment,
      this Agreement  shall terminate in the event SGPF fails to comply with the
      payment  schedule  set forth in  Section  2.1 above,  to the  extent  such
      payments are triggered;  provided,  however, that there shall be a fifteen
      (15) day cure  period  after  receipt of notice of any  non-compliance  by
      SGPF.  There is no cure  period  with  respect to the  Initial  Technology
      Transfer Payment.

            (b)  SGPF may  terminate any further  obligations  it may have under
      this  Agreement by giving notice in writing to Visual  Connections  in the
      event Visual  Connections is in material  breach of this Agreement and has
      failed to cure such  breach  within  sixty (60) days of receipt of written
      notice thereof from SGPF.

            (c)  SGPF may  terminate any further  obligations  it may have under
      this Agreement  (including any obligation to pay to Visual Connections any
      royalty payments withheld  pursuant to Section 12.1(b) below)  immediately
      in the event  that a court of  competent  jurisdiction  (i)  holds  that a
      patent  owned by a third party is infringed by reason of SGPF's use of the
      Technology  Rights in the manufacture,  sale or use of the Products or the
      Technology or (ii) holds that any of the Patents are invalid.

      9.2 Payment Offset. If any of the representations and warranties by Visual
Connections  set forth in Section 7 are or become  inaccurate or breached in any
material respect,  SGPF, in addition to SGPF's other rights under this Agreement
and at law or in equity, will be entitled to a reduction in such amounts payable
or paid by SGPF under this Agreement, such refund and reduction to be in such an
amount or amounts as will compensate SGPF for its damages  incurred by reason of
the  inaccuracy  or breach and  compensate  SGPF for the loss of value in rights
granted to SGPF under this  Agreement as compared  with the value of such rights
in the absence of such inaccuracy or breach.

      9.3 Rights and Obligation on  Termination.  In the event of termination of
this  Agreement for any reason,  the parties will have the following  rights and
obligations:

            (a)  If SGPF has paid  Visual  Connections  the  initial  Technology
      Transfer  Payment pursuant to Section 2.1, then SGPF will retain ownership
      of the  Technology  Rights.  If SGPF has not paid Visual  Connections  the
      Technology Transfer Payment, then

                                       15
<PAGE>

      SGPF  shall  lose any and all  right,  title  and  interest  in and to the
      Patents,  Patent  Applications,  Trademarks,  Technology,  and  Technology
      Rights.

            (b) SGPF will remain  responsible  for payment of any amounts due to
      Visual  Connections  that  has  accrued  prior  to the  effective  date of
      termination  of this Agreement by SGPF subject to the set off described in
      Section 9.2; provided, however, that if upon termination of this Agreement
      SGPF has not  acquired  the  Technology  Rights  then SGPF  shall  have no
      further  obligation  to pay  any  additional  portion  of  the  Technology
      Transfer Payment.

            (c) Sections 10 and 11 will survive termination of this Agreement.

            (d) SGPF,  SGPF's  Affiliates and sublicensees  will be permitted to
      sell any inventory of Product on hand at the effective date of termination
      for a period of one hundred and twenty (120) days from the effective  date
      of  termination  of this  Agreement,  provided  that no  provision of this
      Agreement  will prevent  SGPF,  SGPF's  Affiliates  or  sublicensees  from
      selling  Products  after  termination  of this  Agreement  if the relevant
      Technology  Rights  have  expired  or SGPF is the owner of the  Technology
      Rights.  Visual  Connection  shall have the right to buy all  inventory of
      Product on hand at SGPF's  cost at the end of the one  hundred  and twenty
      (120) day period after the effective date of termination.

10.   Confidentiality; Non-Competition

      10.1  Confidentiality.  Visual  Connections  and  Asbaghi  agree  to  keep
strictly  confidential  and not to disclose  to any third  party any  knowledge,
know-how, practice, process or other information relating to the Technology, the
Technology Rights or the Product, or any information  provided by SGPF to Visual
Connections pursuant to Section 6; provided,  however, that such information (a)
was not in the public domain at the time of  disclosure  to the third party,  or
(b) is required to be disclosed to a government  entity, in which case SGPF will
be provided with adequate written notice and given every reasonable  opportunity
to protect or contest such governmental disclosure.  Visual Connections will use
all  reasonable  efforts  to  ensure  that  none  of its  agents,  employees  or
representatives  violate the provisions of this Section 10.1. Visual Connections
understands  that if it fails to fulfill its obligation under this Section 10.1,
the damages to SGPF would be very  difficult  to  determine.  In addition to any
rights or remedies available to SGPF at law, in equity or by statute, therefore,
Visual Connections  hereby consents to the specific  enforcement of this Section
10.1 by SGPF through an injunction or restraining order issued by an appropriate
court prohibiting the continuance of any violation by the breaching party.

      10.2  Non-Competition  Agreement.  The parties  agree that, as a condition
precedent  to this  Agreement,  Asbaghi  will  execute  and  deliver to SGPF the
Non-Competition  Agreement  attached  hereto as Exhibit  B. The  Non-Competition
Agreement  will  immediately  terminate if Visual  Connections  terminates  this
Agreement  because of SGPF's failure to make the Technology  Transfer Payment as
set forth in Section 2.1 above.

11.   Indemnification

                                       16
<PAGE>

      11.1  Indemnification  by  Visual  Connections.   Visual  Connections  and
Asbaghi,  jointly and  severally,  agree to defend,  indemnify and hold harmless
SGPF  and  its  respective  directors,   representatives,   officers,  managers,
employees,  agents,  shareholders  or  consultants,  from and against any claim,
demand, loss, damage (including  consequential and incidental damages),  cost or
expense (including, without limitation,  reasonable attorneys' fees and expenses
including  costs of  investigation),  or  diminution  of value,  whether  or not
involving a third party claim,  suffered or incurred by SGPF in connection with:
(a)  the  failure  of  any of  the  representations  and  warranties  of  Visual
Connections  contained  in this  Agreement  to have been true and correct in all
respects,  including without limitation those representations and warranties set
forth in Section 7.4 above; and (b) the failure of Visual  Connections to comply
with any of the covenants or provisions  contained in this  Agreement  which are
required to be performed by Visual Connections.

      11.2  Indemnification  by SGPF. SGPF agrees to defend,  indemnify and hold
harmless  Visual  Connections  and its  respective  directors,  representatives,
officers,  managers,  employees,  agents, shareholders or consultants,  from and
against any claim, demand, loss, damage (including  consequential and incidental
damages), cost or expense (including, without limitation,  reasonable attorneys'
fees and expenses  including  costs of  investigation),  suffered or incurred by
Visual  Connections in connection  with personal  injury,  product  liability or
warranty claims of third parties related to any of the Products  manufactured by
or for SGPF.

      11.3 Notice and Procedure. In the event any claim or demand is asserted or
any legal  proceeding  is  threatened  or instituted by any person in respect of
which indemnification may be sought by an indemnified party pursuant to Sections
11.1 or 11.2, the indemnified  party will notify the indemnifying  party thereof
within a reasonable period of time. The indemnifying  party will thereafter,  at
its  expense,  defend  against,  negotiate,  settle or  otherwise  deal with any
proceeding,  claim or demand,  provided,  however that the indemnified party may
participate  in any  proceeding  with counsel of its choice at its expense.  The
parties will  cooperate  fully with each other in  connection  with the defense,
negotiation  or  settlement  of any such  legal  proceeding,  claim  or  demand;
provided, however, that the indemnifying party will not settle any claim, demand
or proceeding  without the consent of the  indemnified  party(ies)  with respect
thereto, which consent will not be unreasonably withheld.

12.   Miscellaneous Provisions

      12.1 Infringement or Invalidity Actions or Proceedings.

            (a)  Cooperation.  In any suit,  proceeding or dispute involving (i)
      the  infringement of any Patent within the Technology  Rights (or alleging
      infringement of a patent or other  intellectual  property owned by a third
      party by reason of SGPF's use of the Technology Rights in the manufacture,
      sale or use of the  Products  or the  Technology)  or (ii) claims that any
      such Patent or Patent Application is invalid, then Visual Connections will
      provide SGPF with reasonable  cooperation  including,  but not limited to,
      becoming party to such suit,  proceeding or dispute, and, upon the request
      and at the expense of SGPF,  Visual  Connections  will make  available  to
      SGPF, at reasonable times and under appropriate  conditions,  all relevant
      personnel, records, papers, information,  samples, specimens, and the like
      in its possession.

                                       17
<PAGE>

      (b) Payment of Royalties.

            (i)   If any suit,  action or proceeding is brought (i) against SGPF
                  alleging the  infringement  of a patent or other  intellectual
                  property owned by a third party by reason of SGPF's use of the
                  Technology  Rights  in  the  manufacture,  sale  or use of the
                  Products  or  (ii)  alleging  the  invalidity  of  any  of the
                  Patents,  then  during the  pendency  of such suit,  action or
                  proceeding,  and  provided  that  SGPF is  unable  to sell the
                  Product or in its  discretion  decides not to sell the Product
                  as a  result  of such  suit or  proceeding,  SGPF  will not be
                  required to make any payments to Visual  Connections  pursuant
                  to Section 2.3.  Promptly  after the  dismissal of such matter
                  (or settlement on terms reasonably  acceptable to SGPF),  SGPF
                  shall  resume  making  such  payments  to  Visual  Connections
                  pursuant  to  Section  2.3 and  shall  pay the  amount  of the
                  withheld royalty payments to Visual Connections.

            (ii)  SGPF, at its sole discretion,  may develop a written plan that
                  will  provide  Visual  Connections  with  the  opportunity  to
                  convert portions,  or all, of its royalty payments into equity
                  interests in SGPF or a successor to SGPF ("the  Royalty  Stock
                  Option  Plan ").  SGPF will use its best  efforts  to make the
                  Royalty Stock Option Plan  transferable to any SGPF successor.
                  Such  Royalty  Stock  Option  Plan  shall not be adopted if it
                  would result in an expense under generally accepted accounting
                  principals  or  under  tax law or  would  interfere  with  any
                  initial public offering by SGPF or its successor.

      12.2 SGPF  Decision.  Notwithstanding  anything  to the  contrary  in this
Agreement, SGPF may, at its sole discretion, determine whether or not to proceed
with  development,  production  and/or  distribution of the Product.  SGPF shall
notify Visual Connections of any such decision not to proceed,  and its reasons,
in writing.  In the event that SGPF's decision to discontinue such  development,
production and/or distribution of the Product is based upon unfavorable economic
conditions,   technological   obsolescence,   patent  infringement   claims,  or
prohibitive  governmental  regulations,  the Technology  Transfer Payment as set
forth in Section 2.1 above will  constitute its entire  financial  obligation to
Visual Connections.

      12.3 Patent Prosecution.  From and after the date of this Agreement,  SGPF
shall be solely  responsible for the prosecution of the Patent  Applications and
the Patents before the applicable  governing  examining  authorities,  excluding
Visual  Connections   responsibilities  as  stated  in  Section  5  and  Section
2.3(b)(iv)  hereof.   SGPF  shall  timely  pay,  when  due,  all  filing  and/or
maintenance  fees for any of such Patent  Applications and Patents in accordance
with applicable law and regulations.  SGPF shall also be solely  responsible for
all  of  the  expenses  incurred  by  it  in  connection  with  prosecuting  and
maintaining  such patent rights.  SGPF and Visual  Connections  shall  cooperate
fully with each other to execute  all  necessary  documentation  to enable  each
party to  perform  its duties and  exercise  its rights  under the terms of this
section.

      12.4  Permits.  From and after the date of this  Agreement,  SGPF shall be
solely responsible,  except for Visual Connections responsibilities as stated in
Section  5 and  Section  2.3(b)(iv)  hereof  for  obtaining  (a)  all  consents,
approvals, governmental filings, authorizations,

                                       18
<PAGE>

and permits for (i) the  consummation of the  transactions  contemplated by this
Agreement  and  (ii)  the  continued  manufacture,  distribution  and use of the
Product, including,  without limitation, any clearance certificates or marketing
approvals  issued  by  the  FDA,   relating  to  the   manufacture,   marketing,
distribution  or use of the Product;  and (b) SGPF shall  maintain in full force
and effect and renew in a timely manner, when required, all Permits.

      12.5 Amendment and Modification.  This Agreement may be amended,  modified
or supplemented only by written agreement of all the parties hereto.

      12.6 Amendment and Modification.  Except as otherwise provided  hereunder,
neither this  Agreement  nor any right or  obligation  arising  hereunder may be
assigned by either party hereto, in whole or in part,  without the prior written
consent  of the other  party  hereto,  which  may be  withheld  in the  absolute
discretion of such other party, and any attempted assignment in violation of the
terms hereof will be null and void and of no force or effect; provided, however,
that either party may assign this Agreement to a purchaser of substantially  all
of the  business of such party  without the prior  written  consent of the other
party  hereto,  so long as such  purchaser  agrees in writing to be bound by the
terms and  conditions  of this  Agreement as though such  purchaser  were Visual
Connections or SGPF, as the case may be. Subject to the foregoing sentence, this
Agreement will be binding upon and inure to the benefit of the parties and their
respective successors and assigns. Notwithstanding anything in this Agreement to
the contrary,  SGPF may sell, transfer or assign all or substantially all of the
Technology  Rights and all of its rights and obligations under this Agreement so
long as the purchaser  agrees in writing to be bound by the terms and conditions
of this Agreement as though such  purchaser were SGPF,  including any obligation
to make Royalty Payments under this Agreement.

      12.7  Entire  Agreement;   Severability.  This  Agreement,  including  the
Exhibits  attached hereto which are incorporated  herein by reference,  contains
the entire  agreement  between  the parties  relating  to the matters  addressed
herein,  and  consequently,  all  prior  and  contemporaneous  oral and  written
discussions and understandings are superseded.  If one or more of the provisions
of  this  Agreement  or  any  application   thereof  are  invalid,   illegal  or
unenforceable in any respect,  the validity,  legality and enforceability of the
remaining  provisions  and  any  other  application  thereof  will  in no way be
affected  or  impaired  and any such  provision  will be enforced to the maximum
extent possible by law.

      12.8 Counterparts.  This Agreement may be executed in counterparts, all of
which taken together will constitute a single Agreement,  or by the execution of
a separate agreement under the terms of which the person executing such separate
agreement  specifically  undertakes  to be bound by the  terms,  provisions  and
agreements of this Agreement.

      12.9 Governing Law, Consent to Jurisdiction.  Unless otherwise agreed upon
in writing between the parties,  this Agreement and the legal relations  created
by it will in all  respects,  including,  without  limitation,  with  respect to
construction,  interpretation,  performance, effect and remedies, be governed by
and  construed in  accordance  with the  internal  laws of the State of Delaware
(without  regard to the laws of conflict of any  jurisdiction),  except that the
laws of the  United  States  will apply to  questions  regarding  the  validity,
infringement or  enforceability  of U.S.  patents rights relating to the subject
matter of this Agreement.  Each party hereto irrevocably consents that any legal
action or proceeding  against it occurring  under,  relating to or in connection
with this Agreement or any other agreement,  document or instrument  arising out
of

                                       19
<PAGE>

or executed in connection  with this Agreement may be brought only in a court of
the state of Delaware or in the United States District Court for the District of
Delaware,  but that each party  consents and agrees that any  litigation  should
occur in the Delaware Chancery Courts, if jurisdiction exists. Each party by the
execution and delivery of this Agreement  expressly and irrevocably  assents and
submits to the personal jurisdiction of any of such courts in any such action or
proceeding.  Each  party  further  irrevocably  consents  to the  service of any
complaint,  summons,  notice or other  process  relating  to any such  action or
proceeding by delivery  thereof to it by hand or by mail in the manner  provided
for in Section 12.11 hereof.  Each party hereby expressly and irrevocably waives
any claim or defense in any action or  proceeding  based on any alleged  lack of
personal  jurisdiction,  improper  venue or forum non  conveniens or any similar
basis.

      12.10 Certain Agreements; Additional Documents and Acts. Each party agrees
to  cooperate  and to execute and deliver in a timely  fashion  such  additional
documents  and  instruments  and  to  perform  such  additional  acts  as may be
necessary  or  appropriate  to effect,  carry out and  perform all of the terms,
provisions,  and conditions of this Agreement and the transactions  contemplated
hereby.

      12.11 Notices.  Any notice,  request,  instruction or other document to be
given  hereunder  by any party  hereto to any other party must be in writing and
delivered  personally or sent by registered or certified  mail,  postage prepaid
(and if by mail with a copy sent by telephonic facsimile transmission),

         If to Visual Connections:

                              Visual Connections, Inc.
                              Attn: Hooman Asbaghi
                              3414 Jackdaw Street
                              San Diego, CA 92103
                              Phone: 858-342-1789
                              Fax: 619-293-0454

         If to Asbaghi:

                              Hooman Asbaghi
                              3414 Jackdaw Street
                              San Diego, CA 92103
                              Phone: 858-342-1789
                              Fax: 619-293-0454

         If to SGPF:

                              SGPF, LLC
                              Attn: Walter Weller
                              817 Winchester Road, Suite 200
                              Lexington, Kentucky  40505
                              Phone: 859-225-5375

                                       20
<PAGE>

                              Fax: 859-225-5347

      or at such other  address for a party as is specified by like notice.  Any
      notice which is addressed and mailed in the manner herein provided will be
      deemed to have been duly  given to the party to which it is  addressed  on
      the date  deposited  in the mail  (or,  if  later,  the date of  facsimile
      transmission).

      12.12  Force  Majeure.  If either  party is delayed in or  prevented  from
performing any obligation  hereunder due to any act of God, fire, riot, embargo,
or strike or other labor problem, availability of Product materials,  unforeseen
and dramatic increases in Product production costs that eliminate the ability to
allow  commercialization the Product, then such delay or nonperformance shall be
excused and the time for  performance  shall be extended  during the pendency of
such  condition.  Time is of the  essence  in  performance  of the terms of this
Agreement.

      12.13 Exhibits.  Exhibits attached hereto are incorporated  herein in full
by this reference as if each of such exhibits were set forth in the body of this
Agreement and duly executed by the parties hereto.

      12.14  Waivers.  Neither the waiver by a party of a breach of or a default
under any of the provisions of this  Agreement,  nor the failure of a party,  on
one or more occasions,  to enforce any of the provisions of this Agreement or to
exercise any right,  remedy or privilege  hereunder will thereafter be construed
as a waiver of any such provisions, rights, remedies or privileges hereunder.

      12.15  Exercise  of Rights.  No failure or delay on the part of a party in
exercising  any right,  power or  privilege  hereunder  and no course of dealing
between the parties  will  operate as a waiver  thereof,  nor will any single or
partial exercise of any right,  power or privilege  hereunder preclude any other
or  further  exercise  thereof  or the  exercise  of any other  right,  power or
privilege.  The rights and remedies herein expressly provided are cumulative and
not  exclusive  of any  other  rights or  remedies  which a party  hereto  would
otherwise have at law in equity or otherwise.

      12.16 Pronouns.  All pronouns and any variations thereof will be deemed to
refer to the masculine, feminine, neuter, singular or plural, as the identity of
the person or entity may require.

      12.17 Headings.  Section headings contained in this Agreement are inserted
for  convenience  of  reference  only,  will not be  deemed to be a part of this
Agreement for any purpose, and will not in any way define or affect the meaning,
construction or scope of any of the provisions hereof.

      12.18 Survival.  It is the express  intention and agreement of the parties
that all  covenants,  agreements,  statements,  representations,  warranties and
indemnities  made in this  Agreement  will survive the execution and delivery of
this  Agreement  and,  where  appropriate  to  facilitate  the  intent  of  this
Agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

                                       21
<PAGE>

      The parties  hereto have duly  executed  this  Agreement as of the day and
year first above written.

SGPF, LLC                                    VISUAL CONNECTIONS, INC.
a Kentucky limited liability company         a California corporation

By:  /s/ Walter W. Weller                    By:  /s/ Hooman Asbaghi
   ------------------------------------         --------------------------------
   Walter W. Weller                             Hooman Asbaghi, President

     /s/ Hooman Asbaghi
---------------------------------------
Hooman Asbaghi

                                      S-1
<PAGE>

                                    Exhibit A

   Description of Safety Syringe System, with and without a Distal Protective
               Needle, in a Fillable and Pre-filled Configuration

The  patents  as  described  in  Recital  A of this  Agreement  provide  for the
following device configurations, as described generally below:

PRODUCT DESCRIPTIONS:

      1.    Passively guarded 1ml syringe with and without "blunt" needle.

      2.    Passively guarded 3ml syringe with and without "blunt" needle.

      3.    Passively  guarded 1ml syringe without a needle.  (All product sizes
            about 5ml are the same design).

      4.    Passively guarded 1ml pre-filled syringe with a detached  cartridge.
            (The cartridge can be either glass or plastic).

      5.    Hypodermic needle with "blunt" needle attached to it.

<PAGE>

                                    Exhibit B

                            NON-COMPETITION AGREEMENT

      This  Agreement,  effective  as of  February  19th,  2007 (the  "Effective
Date"),  by and between  SGPF,  LLC a Kentucky  limited  liability  company (the
"Marketing Company"), and Hooman A. Asbaghi, an individual resident of the State
of California ("Hooman") as of the date of this Agreement.

      A.  Hooman  is a  principal  shareholder  of Visual  Connections  ("Visual
Connections").

      B. Visual  Connections  desires to enter into that certain  Agreement (the
"Technology  Acquisition  Agreement") with SGPF and Hooman, dated as of February
19th, 2007, from which Hooman will directly receive substantial consideration as
a stockholder of Visual Connections.

      C. SGPF  requires,  as a condition to its entry into the  Agreement,  that
Hooman enter into this Agreement.

      In consideration of the premises and mutual  covenants  contained  herein,
and intending to be legally bound, the parties agree as follows:

      1.  Non-Compete.  During the Non-Compete  Period (as defined below) Hooman
will not, alone, or in any capacity with another firm,  within any  geographical
area in which SGPF, at the time of the execution of this  Agreement,  is engaged
in more than an insignificant volume of business:

      (a)  directly  or  indirectly  participate  in or support in any  capacity
(e.g., as an advisor, principal, agent, partner, officer, director, shareholder,
employee  or  otherwise)  the   manufacture,   invention,   development,   sale,
solicitation of sale, marketing,  testing,  research or other business aspect of
any actual or projected  product,  product line or service designed,  developed,
manufactured,  marketed or sold by anyone other than SGPF that performs  similar
functions or is used for the same general  purposes as a Product,  as defined in
the Technology Acquisition Agreement, or otherwise competes with exploitation of
the technology  described on the Description of the Safety Syringe System,  with
and  without  a  Distal   Protective   Needle,  in  a  Fillable  and  Pre-filled
Configuration attached to the Technology Acquisition Agreement as Exhibit A.

      (b) call upon, solicit, contact or serve any of the then-existing clients,
customers, vendors or suppliers of SGPF or its marketing representative(s),  any
clients, customers,  vendors or suppliers that have had a relationship with SGPF
or its marketing  representative(s)  during the preceding twelve (12) months, or
any potential  clients,  customers,  vendors or suppliers that were solicited by
SGPF or its marketing representative(s) during the preceding twelve (12) months;

      (c)  disrupt,  damage,  impair or  interfere  with the  business  of SGPF,
whether  by way of  interfering  with or  disrupting  SGPF's  relationship  with
employees, customers, agents, representatives or vendors; or

<PAGE>

      (d) employ or attempt to employ (by soliciting or assisting anyone else in
the  solicitation  of) any of SGPF's  employees  on behalf of any other  entity,
whether or not such entity competes with SGPF.

      2.  Non-Compete  Period.  For  purposes  of this  Agreement,  "Non-Compete
Period" means the term of this  Agreement,  which shall continue for the term of
the  Technology  Acquisition  Agreement  and  a  further  period  of  12  months
thereafter.

      3. Exceptions to Non-Compete. The restrictions contained in this Agreement
will not  prevent  Hooman from  accepting  employment  with a large  diversified
organization  with  one or more  separate  and  distinct  divisions  that do not
compete,  directly or indirectly,  with SGPF, as long as prior to accepting such
employment  SGPF  receives  separate  written  assurances  from the  prospective
employer and from Hooman,  satisfactory  to SGPF, to the effect that Hooman will
not render any  services,  directly or  indirectly,  to any division or business
unit that competes,  directly or indirectly,  with SGPF.  During the Non-Compete
Period, Hooman will inform any new employer,  prior to accepting employment,  of
the  existence of this  Agreement  and provide such employer with a copy of this
Agreement.  Notwithstanding  anything to the  contrary in this  Agreement,  this
Agreement  will  immediately  terminate  if Visual  Connections  terminates  the
Technology  Transfer  Agreement because of SGPF's failure to make the Technology
Transfer  Payment  as set  forth  in  Section  2.1 of  the  Technology  Transfer
Agreement. The parties understand and acknowledge that Hooman has previously, is
currently  involved in and anticipates  continuing to be involved in the design,
development  and sale and/or  licensing of various other types of safety needles
for the  healthcare  industry  unrelated to a passive  safety  blood  collection
holder.  SGPF acknowledges that Hooman's activities and involvement as described
in the preceding  sentence  shall not constitute any breach or violation of this
Agreement.

      4. Remedies.  Hooman acknowledges that if he breaches this Agreement, SGPF
will be irreparably and immeasurably injured.  Therefore,  Hooman agrees that in
addition to any other remedies  available to SGPF,  SGPF may apply to a court of
competent jurisdiction for a temporary and/or permanent injunction and that such
court may grant such injunction to restrain and prohibit such breach by Hooman.

      5.  Assignments.  This  Agreement  is  personal  to Hooman  and may not be
assigned or delegated by Hooman or transferred in any manner whatsoever, nor are
such obligations subject to involuntary alienation, assignment or transfer. This
Agreement  will inure to the benefit of and be  enforceable  by  Hooman's  legal
representatives.  This  Agreement is binding on and inures to the benefit of the
Company's successors and assigns.

      6.  Nonwaivers  of  Rights.  No failure or delay on the part of a party in
exercising any right hereunder will operate as a waiver of, or impair,  any such
right.  No single or partial  exercise of any such right will preclude any other
or further exercise thereof or the exercise of any other right. No waiver of any
such right will be effective unless given in a signed writing.  No waiver of any
such right will be deemed a waiver of any other right hereunder.

      7.  Validity  of  Provisions;  Severability.  If  any  provision  of  this
Agreement is or becomes or is deemed invalid,  illegal,  or unenforceable in any
jurisdiction, (a) such provision

                                      S-4
<PAGE>

will be deemed amended to conform to applicable laws of such  jurisdiction so as
to be valid and enforceable,  (b) the validity,  legality and  enforceability of
such provision will not in any way be affected or impaired  thereby in any other
jurisdiction  and (c) the remainder of this  Agreement will remain in full force
and effect.

      8.  Governing  Law,  Consent  to  Jurisdiction.  This  Agreement  has been
negotiated  and entered  into in the state of  Delaware,  will be deemed to be a
Delaware  contract  and  will  be  governed  by  the  laws  of  Delaware  as  to
interpretation  and performance  without reference to principles of conflicts of
laws.  Each  party  irrevocably  consents  that any legal  action or  proceeding
against it occurring under,  relating to or in connection with this Agreement or
any other  agreement,  document  or  instrument  arising  out of or  executed in
connection  with  this  Agreement  may be  brought  in a court  of the  state of
Delaware or in the United  States  District  Court for the District of Delaware.
Each  party by the  execution  and  delivery  of this  Agreement  expressly  and
irrevocably  assents and  submits to the  personal  jurisdiction  of any of such
courts  in any such  action or  proceeding.  Each  party  hereby  expressly  and
irrevocably waives any claim or defense in any action or proceeding based on any
alleged lack of personal  jurisdiction,  improper venue or forum non convenes or
any similar basis.

      The parties have  executed this  Agreement  effective the date first above
written.

SGPF, LLC                                    HOOMAN A. ASBAGHI
---------                                    -----------------

By:  /s/ Walter W. Weller                      /s/ Hooman A. Asbaghi
   ------------------------------------      -----------------------------------
   Walter W. Weller                          Hooman A. Asbaghi

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]